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ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia in elderly 
population, affecting more than 35 million people worldwide. To date, the only 
approved therapies for AD focus on symptomatic relief. The development of new 
therapeutic agents is time consuming and costly. Drug discovery process is 
arduous because clinical trials are currently involving too wide sample of patients 
and long follow-up. Moreover, the predicting value of experimental models used 
nowadays is limited due to the lack of homologous markers in humans and 
animals. 
This work is a branch of Pharmacog, an industry-academic European project 
aimed at identifying reliable biomarkers that are sensitive to disease progression in 
patients with Mild Cognitive Impairment (MCI) and in AD animal models in order to 
bridge the gap between preclinical and clinical outcomes. Human neuroimaging 
markers are among the most promising candidates to track disease progression. In 
addition, advanced magnetic resonance imaging (MRI) allow the identification of 
homologous biomarkers in humans and mice. Prior to investigate neuroimaging 
biomarkers on MCI patients, we have to test that there is no significant effect of 
within and across MRI sites variability on brain AD-related longitudinal changes. 
The first aim of this work is the study of the morphometric and diffusion changes in 
three different AD mouse model (TASTPM, TauPS2APP and PDAPP from 3 to 22 
months of age) through MRI. We found significant volume reduction starting at 9 
months in the caudate-putamen and frontal cortex of TASTPM and TauPS2APP 
(p< 0.001) compared to non transgenic mice. The decrease in the enthorinal cortex 
thickness was significantly lower in all the strains (p< 0.001). We also found age-
related diffusion abnormalities in different white matter regions of TASTPM. The 
earlier changes were found in the corpus callosum and anterior commissure of 13 
months old mice (p< 0.001). In TASTPM, deficits detected with MRI are related to 
heavy amyloid pathology, marked gliosis and astrocitosys.  
The second aim of this study is the evaluation and comparison of test-retest 
reproducibility of brain volumes and thicknesses by two existing Freesurfer 
pipelines (longitudinal and cross-sectional). Moreover, we assessed the reliability 
of a diffusion pipeline developed in our lab. Eight different 3T MRI sites in Europe 
enrolled a group of 5 healthy elderly subjects scanned twice at least a week apart. 
We found that the within and across sites variability of volumes was less than 3% 
for larger brain structures (such as thalamus) and less than 6% for smaller regions 
(i.e., hippocampus). The thickness variability was less than 6% and diffusion 
indices variations were mostly within the range 2-3%. 
In conclusion, the present data identify imaging biomarkers of disease progression 
in mice similar to that seen in humans and pave the way of a murine “imaging 
signature” usefulness in clinical trials. Human data show significantly higher 
reproducibility of brain morphometry using the longitudinal pipeline than using the 
cross-sectional one (p< 0.01). Finally, we demonstrated that the reliability of the 
analysis of brain diffusion we implemented in our lab is comparable to data 
reported in the literature. 
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La Malattia di Alzheimer (AD) è la forma più comune di demenza nella popolazione 
anziana e affligge più 35 milioni di persone nel mondo. Ad oggi, le uniche terapie 
approvate per la sua cura sono dirette a ridurre i sintomi. Lo sviluppo di nuovi 
farmaci è lungo e costoso. Il processo di scoperta è arduo in quanto i trial clinici 
coinvolgono un ampio campione di pazienti e implicano dei follow-up troppo lunghi. 
Inoltre il valore predittivo dei modelli sperimentali è limitato a causa della 
mancanza di marcatori omologhi nell’uomo e nei modelli animali.  
Questo lavoro si inserisce in Pharmacog, un progetto europeo che vede la 
collaborazione di università ed industrie allo scopo di identificare biomarcatori 
affidabili e sensibili alla progressione di malattia in pazienti affetti da decadimento 
cognitivo lieve (MCI) e modelli animali di AD allo scopo di colmare il vuoto tra 
risultati clinici e preclinici. Nell’uomo, i marcatori di neuroimmagine sono tra i più 
promettenti candidati nel tracciare la progressione di malattia. Innovazioni nelle 
tecniche di risonanza magnetica (MRI) rendono possibile l’identificazione di 
marcatori omologhi nell’uomo e nel topo. Prima dello studio di neuroimmagine nei 
pazienti MCI, è necessario verificare che eventuali cambiamenti individuati siano 
dovuti all’effettiva progressione di malattia e non causati dalla variabilità intra e tra i 
diversi scanner utilizzati nel progetto. 
Il primo scopo di questo lavoro è lo studio dei cambiamenti morfometrici e di 
diffusione in tre diversi modelli murini di Malattia Alzheimer (TASTPM, TauPS2APP 
e PDAPP da 3 a 22 mesi) tramite l’utilizzo di tecniche MRI. A nove mesi abbiamo 
trovato una significativa riduzione rispetto ai controlli del volume del caudato-
putamen e della corteccia frontale nei TASTPM e nei TauPS2APP (p< 0.001). 
L’assottigliamento della corteccia entorinale era significativo alla stessa età in tutte 
e tre i modelli (p< 0.001). Abbiamo inoltre individuato delle anormalità dipendenti 
dall’età anche in diverse regione di sostanza bianca. Quelle più precoci erano nella 
commissura anteriore e nel corpo calloso dei TASTPM di 13 mesi (p< 0.001). I 
danni dei TASTPM sono associabili al pesante carico di amiloide ed alla marcata 
attivazione della glia e degli astrociti.  
Il secondo scopo dello studio è la valutazione e la comparazione della 
riproducibilità di misure volumetriche e di spessore tra test e retest ottenute 
utilizzando due diversi metodi di processazione esistenti (Freesurfer sulla singola 
acquisizione o Freesurfer longitudinale). Inoltre abbiamo saggiato la riproducibilità 
di un’analisi per le immagini di diffusione messa a punto nel nostro laboratorio. A 
questo scopo ognuno degli otto centri europei coinvolti nel progetto e con diversi 
scanner a 3T ha arruolato un gruppo di 5 volontari sani e anziani sottoponendoli a 
2 acquisizioni di risonanza ad almeno una settimana di distanza l’una dall’altra. 
Abbiamo trovato che la variabilità intra e tra i diversi centri nei volumi estratti da 
queste acquisizioni era inferiore al 3% per le strutture più grandi (come il talamo) e 
minore del 6% per quelle più piccole (es. amigdala). La variabilità degli spessori 
era meno del 6% e le variazioni dei parametri di diffusione erano prevalentemente 
nell’intervallo del 2-3%. 
In conclusione, abbiamo identificato nei modelli analizzati dei marcatori di 
immagine sensibili alla progressione dell’AD simili a quelli visti nell’uomo e questo 
apre la strada al possibile utilizzo di una “distintiva collezione” di marcatori murini di 
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immagine nei trial clinici. I dati collezionati nella parte umana mostrano un più altra 
riproducibilità dei risultati morfometrici ottenuti con l’analisi longitudinale rispetto a 
quella sulla singola acquisizione (p< 0.01). Infine, abbiamo dimostrato che l’analisi 
delle immagini di diffusione messa a punto nel nostro laboratorio dà risultati 
ugualmente riproducibili a quelli riportati in letteratura. 
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1 ALZHEMER DISEASE 
1.1 Introducion 
Alzheimer’s disease (AD) is the most common form of dementia in elderly people 
affecting more than 35 million people worldwide [1]. Its incidence increases 
exponentially with age [2] and the median survival time from diagnosis is around 
three-ten years [3]. AD is characterized by the deterioration of memory, behaviour, 
emotion and cognition. Most AD cases are sporadic with unknown causes, 
whereas the familial or inherited form of AD (FAD), accounting for only 1-10% of 
cases, presents several autosomal dominant mutations. AD brains are 
characterized by the accumulation of two major protein: β-amyloid (Aβ) and hyper-
phosphorylated tau. The former constitutes extracellular deposits [4] in the 
parenchyma and in brain vessels, the latter forms intracellular neurofibrillary 
tangles (NFT) [5, 6]. Synaptic impairment, metabolic deficits, neuronal loss and 
inflammation are also present. The pathological process starts years before the 
appearance of clinical symptoms and progressively gets worst with time [7].  
AD was discovered in 1906 by Alois Alzheimer from whom the pathology takes its 
name; he reported the case of Auguste D., a 51-year-old woman presenting 
several of the cardinal features observed in most patients nowadays. In the middle 
1980s the Aβ peptide, the main component of amyloid plaques, was purified and 
sequenced [8, 9], giving rise to the “amyloid hypothesis” of AD, which suggests an 
initiating role of Aβ in the kickoff of the degenerative process where loss of tau 
physiological functions is required to elicit symptoms.  
1.2 Clinical utility of biomarkers in AD 
There are two distinct approaches for the treatment of AD: symptomatic relief (i.e., 
improvement of cognitive performance) and disease modification (i.e., prevention, 
slowing or reversal of the underlying pathological processes). To date, the only 
approved therapies for AD focus on symptomatic relief because any drug has 
convincingly shown disease modifying effects. The development of therapeutic 
agents in this field is time consuming, costly and continuous to delay the effective 
treatments of patients [10]. Drug discovery process is challenging because clinical 
trials are currently implicating wide sample size and follow-up for as far as 18 
months [11]. Moreover, experimental models recapitulating the main pathological 
characteristics of AD have not yet been engineered and this might explain the 
unexpected results and failure of the numerous clinical trials carried out so far. 
Identifying biomarkers sensitive to disease progression is fundamental for 
diagnostic purpose and to accelerate the clinical application of novel therapeutic 
agents [12]. Pharmacog is an industry-academic European project aimed at 
identifying reliable biomarkers that are sensitive to disease progression in patients 
with Mild Cognitive Impairment (MCI) and animal models to bridge the gap 
between preclinical and clinical outcomes. Longitudinal studies in patients with 
MCI, who have a high risk of developing AD, and animals will improve our 
capability to selectively quantify the pathological progressive changes and thus 
discover and define novel indices of disease progression in both. An ideal 
translatable biomarker of disease progression should be identified in humans and 
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have a similar history in animals. Moreover, it should give reliable results in drug 
testing allowing translatable therapeutic considerations for human patients. 
Recently a biomarker model of the preclinical AD has been proposed [13] (Fig 1a). 
The pathologic markers variations can be temporally divided in i) amyloid β (Aβ) 
deposition, evaluated through reduction in CSF Aβ42 and increased in amyloid 
tracer retention on positron emission tomography (PET); ii) synaptic markers 
alterations detected using fluorodeoxyglucose (FDG) uptake on PET and iii) AD-
related neuronal loss on magnetic resonance imaging (MRI) [13]. Transgenic mice 
(Tg) carrying human mutated genes associated to AD, such as amyloid precursor 
protein (APP) or presenilins (PSs), are considered models of preclinical AD 
because they reproduce different pathological features, such as Aβ accumulation 
into amyloid plaques or neurofibrillary tangles or synaptic dysfunction and, as for 
humans, mouse deficits increase with age (Fig 1b). In mice, the protein expression 
pattern depends on the transgene promoter, the amount of amyloid deposition 
seems to be influenced by gene mutation type and genetic background could also 
account for strain differences. Although different complex animal models exist, 
none of them replicates the AD pathology as a whole but animal models are 
available for a number of pathological AD features allowing to translate human 
markers to or develop new ones from mice.  
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Figure 1. Hypothetical model of dynamic biomarkers in human AD (a) [13] 
and pathological AD progression in the most frequently used mice (b). 
Models of amyloidosis are created by deploying one, or a combination of, genes 
that have been found mutated in Familiar AD subjects (such as APP and PS1). 
These mice show structural, functional and biochemical alterations similarly to the 
human pre-clinical stage of AD pathology. Moreover, as for human, mouse deficits 
increase with age. All APP and/or PS1 Tg mouse models do not reproduce tangles. 
Tau pathology can be replicated in mice using modifications in the sequence of tau 
protein discovered in the familiar form of Frontotemporal Dementia with 
parkinsonism linked to chromosome 17 and Tau Tg mice are characterized by 
tangles in absence of Aβ. The triple transgenic mouse model, carrying mutation in 
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APP, PS1 and Tau (3xTg) better reproduces the signature lesions of AD as it 
develops both Aβ and tangles. 
 5 
2 AIM OF THE STUDY  
My work is inside IMI-Pharmacog, an industry-academic European project 
investigating the translational information derived from neuroimaging, biochemical, 
neurophysiological and neuropsychological outcomes in animal models and 
patients with MCI to discover and define novel indices of disease progression in 
both.  
The two main goals of my project were focused on preclinical and clinical 
neuroimaging analysis. The preclinical side was dedicated to study biomarkers 
which are shown to be altered in the human disease [14, 15] and find new ones, in 
three transgenic animal models. Identifying an imaging biomarker signatures in 
mice similar to that seen in MCI patients would improve predictive capacity for the 
clinic. We analyzed in details morphometric and diffusion changes in three different 
AD mouse model, such as TASTPM, TauPS2APP, PDAPP and non transgenic 
(wild-type, WT) mice using different MRI techniques. We limited our investigation to 
the structural outcomes because definition of functional acquisition and analysis 
protocols are still ongoing. The clinical side was to evaluate and minimize the 
across-session test-retest reliability of brain segmentations and diffusion 
parameters derived from a group of different 3T MRI scanners (Siemens, Philips, 
GE) using elderly healthy subjects.  
The work described here is structured in two sections:  
Part I: Animal imaging Performing morphometric and diffusion analysis in 
transgenic mice relative to wild-type using 3D and Diffusion Tensor Imaging (DTI). 
We identified several structural markers sensitive to Alzheimer progression.  
Part II: Human imaging Assessment of morphometric and diffusion measure 
reproducibility in 8 3T sites across Europe using 3D and DTI.  
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3 PART I: ANIMAL IMAGING 
3.1 AD transgenic mice 
Most of the commonly used Tg mice are created by deploying one, or a 
combination of, genes that have been found mutated in Familial AD (FAD) subjects 
such as APP [16, 17] and PSs [18, 19] or in the familial form of Frontotemporal 
Dementia such as tau [20]. While all APP and PSs Tg mouse models do not 
reproduce tangles, Tau Tg mice are characterized by tangles in absence of Aβ 
(Table 1 summarize some of the most used models). 
 
Tg line 
name 
Genetic Mutation Promoter Ref 
PDAPP APPminigene (Indiana: V717F)  PDGFβ [21] 
Tg2576 APP
695 (Swedish: K670N-M671L) 
 Hamster PrP [22] 
APP/PS1KI APP
751 (Swedish and London: V717I)
 / PS1KI Murine Thy-1 (APP and PS1) [23] 
TASTPM APP
695 (Swedish)/ PS1M146V Murine Thy-1 (APP and PS1) [24] 
APP-PS1 APP751 (Swedish and London)/ PS1M146L  PDGFβ (APP) and HMG-CoA 
reductase (PS1) [25] 
PS2APP APP695 (Swedish)/ PS2N141I Murine Thy-1 (APP) and PrP (PS2) [26] 
3xTg 
APP751(Swedish)/ PS1M146V  KI/ 
TauP301L  
Murine Thy-1 (APP, PS1 and 
Tau) [27] 
TauPS2 
APP 
APP695(Swedish)/ PS2N141I/ TauP301L 
Murine Thy-1 (APP),  
PrP (PS2 and Tau) [28] 
 
Table 1. Most frequently used mice models of amyloidosis. PDGFβ (platelet-
derived growth factor β-chain) and PrP (prion protein) result in a transgene 
expression inside and outside of the central nervous system. Thy-1 (thymocyte 
differentiation antigen 1), HMG-CoA reductase (3 hydroxy-3-methylglutaryl-
coenzyme A reductase) and  NSE (neuron-specific enolase) are neuronal specific. 
 
3.1.1 Models of amyloidosis 
Tg mouse models mimicking amyloidosis are created deploying APP and/or PSs. 
APP is a member of type 1 transmembrane family of glicoproteins and is 
proteolytically cleaved by secretases, proteases membrane-associated. α-
secretase begin the nonamyloidogenic processing of APP, generating a large 
soluble peptide (α-sAPP) and a smaller carboxy-terminal fragment (CTF-α). CTF-α 
is a γ-secretase substrate that produces extracellular p3 and the amyloid 
intracellular domain (AICD). Amyloidogenic processing is started by β-site APP-
cleaving enzyme 1 (BACE1) [29, 30], a β-secretase, which creates β-sAPP, larger 
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than α-sAPP, and CTF-β. Also CTF-β is processed by γ-secretase producing Aβ 
and AICD.  
Although the exact physiological significance of APP and the products of its 
cleavage remain to be clarified, different physiological roles have been 
hypothesized including involvement in cell movement [31], apoptosis [32], cell 
differentiation [33], synaptic strength [34] and transcriptional regulation [35]. APP 
FAD mutations can be detected near the β- or γ-secretases cleavage sites, 
facilitating their activity and increasing the secretion of the longer and more toxic 
Aβ peptides, Aβ42 [36], or within Aβ sequence, majoring the capacity to form 
oligomers and protofibrils [37]. 
PSs are transmembrane proteins. Presenilin 1 (PS1) belongs to the γ-secretase 
complex with nicastrin, anterior pharynx defective 1 (APH1) and presenilin 
enhancer 2 (PEN2) [38, 39]. PSs are not only involved in APP processing but they 
are also implicated in neurotransmitter release regulation [40] and directly interact 
with tau and glycogen synthase kinase 3β (GSK-3β) [41], an important enzyme 
involved in tau phosphorylation and essential in the pathogenesis of AD [42]. 
Moreover, PSs probably act as neuronal endothelium reticular calcium leak 
channels [43] and might play another physiological role regulating the intracellular 
trafficking of selected proteins [44-47]. PSs FAD mutations result in an Aβ peptide 
generation increment and cause an imbalance in calcium signalling [48, 49].  
Many Tg models have been created using different promoters, mouse strains or 
sequence mutations but in general the human APP or PS mutated gene 
overexpression results in amyloidosis which leads to the early onset of dementia 
[21, 22, 50, 51]. This phenomenon is even more precocious if these genes are co-
expressed in the same mouse [23, 52, 53]. Unfortunately, atrophy or neuronal loss 
are very rare. To date, an increasing number of evidence indicates the 
accumulation of Aβ peptides localized within the neurons as one of the earliest 
pathological events in AD [54]. Tg mice with intraneuronal Aβ or neuronal loss are 
reviewed in [55]. Beside gene overexpression, another way used to study the role 
of the genes is the knock out technique in which specific genes are unmade. APP 
knock out mice are viable and fertile and show reduced locomotor activity and 
reduced grip strength [56]. PS1-deficient mice die perinatally probably because 
PS1 is involved in Notch signalling pathway [57, 58] and also exerts pleiotropic 
effects during brain development, including the regulation of neurogenesis. For this 
reason a conditional forebrain-specific PS1 knockout mouse, based on Cre/loxP 
system has been created. These mice are normal but deficient in enrichment-
induced neurogenesis. PS2 knockout mice had no abnormal phenotypes [59], 
maybe because its loss of function is covered by PS1. Mice lacking both PS1 and 
PS2 are embryonic lethal too [60] but conditional double knockout mice lacking the 
PSs in the postnatal forebrain are identical to wild type until adulthood and exhibit 
an age-dependent AD-like neurodegenerative phenotypes [61, 62]. BACE1 null 
mice are viable, healthy and fertile. In their adult brains no Aβ production has been 
detected and BACE1 deficient neurons fail to secrete Aβ, even when co-
expressing APP and PS1 mutant genes [63]. 
3.1.2 Models of tauopathy 
Although no tau mutations have been found in AD, NFT, the other principal 
pathological characteristic of this dementia is replicated in mice using modifications 
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in the sequence of tau protein discovered in the familial form of Frontotemporal 
Dementia with parkinsonism linked to chromosome 17 (FTDP-17) [20]. The 
microtubule-associated protein tau (MAPT) gene is located on chromosome 17 and 
more than 30 mutations have been linked to FTDP-17 [64]. The genetic sequence 
alteration influences the presence and the level of fibrillary lesions and NFTs. In 
normal conditions, Tau is a multifunctional protein localized to the axons where is 
associated with microtubules ensuring their stability and their assembly [65]. It is 
also implicated in axonal transport [66], elongation and maturation [67] and in 
facilitating tubulin acetylation [68]. HPτ becomes insoluble, loses its affinity for 
microtubules and forms cytotoxic intermediate aggregates [69] that, successively, 
composed the tangles. The tau phosphorylation status depends on the balance 
between kinases and phosphatases activity and the principal kinases involved in 
tau modifications are GSK-3β [42] and Cyclin-dependent kinase 5 (Cdk5) [70, 71]. 
In adult human brain six tau isoforms exist, all of them have been found in a hyper-
phosphorylated state in neurofibrillary lesions of AD patients [72].  
Tau animals, like amyloidosis models, have been commonly created using 
knockout or overexpression techniques. The former seem linked to normal 
development and mild cognitive deficits although embryonic hippocampal cultures 
from these mice show a significant delay in maturation [67], the latter are linked to 
different phenotypes depending on the transgene and its promoter (for a review 
see [73]). An alternative approach is to create mouse models overexpressing 
kinases involved in tau phosphorylation [74, 75]. 
3.1.3 Models of amyloidosis and tauophaty 
The triple transgenic mouse model (3xTg) seems to be the model which better 
reproduces the signature lesions of AD because of the development of both Aβ 
and tangles [28]. Interestingly, Aβ induces NFTs formation only in mice carrying the 
mutant form of human tau and not the human wild type sequence. This is different 
from AD patients situation, where Aβ aggregation and NFT formation occur in the 
absence of tau pathogenic mutations [76].  
3.2 Tg as model of preclinical AD 
3.2.1 Neuritic alterations 
Neuritic alterations are associated to transport impairment of lipids components 
and membranes proteins along the axons, a critical issue for neuronal functioning 
known as fast axonal transport (FAT). FAT is accountable for the delivery of 
different elements and subcellular structures, such as mitochondria and synaptic 
vesicles, from the sites of their synthesis to their final destination. Histological 
analysis of many mouse models found dystrophic neuritis around and within the Aβ 
deposits [21, 26, 27, 77, 78].  
To date, advanced neuroimaging techniques are possible for the in vivo analysis of 
neuritic structure and functionality of AD animal models, such as Tg mice. DTI 
allows the description of tissue microstructures exploiting the diffusion properties of 
water [79] will be deeply discussed in the section “Structural outcomes” (pag 14). 
MRI using manganese (Mn2+) as contrast agent (MEMRI: Manganese-Enhanced 
MRI) is used to identify and quantify the difference in axonal transport rates in vivo 
because the paramagnetic ion Mn2+ was transported along microtubules via FAT. A 
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study on Tg2576 showed an age-dependent decrement in the axonal transport rate 
within Tg as well as a difference between Tg and controls, with a lower axonal 
transport rate in the Tg (81). It was hypothesized that the decrease in axonal 
transport was related to plaques formation. Although mutated tau alone led to 
axonal transport deficits [80, 81] wild-type tau deletion [67, 82] or overexpression 
[82] were ineffective. Loss of wild-type tau expression had a very different impact 
when mutated APP co-exists [83]. In the Tg2576 for example, extensive 
degeneration of cortical and subcortical neurites, not normally observed, an 
increase in Aβ peptide and more severe cognitive deficits were detected. A recent 
MEMRI-study showed that FAT was reduced by 50% in APP knock out mice since 
early-life [84]. This condition was ameliorated by co-overexpression of human wild-
type tau and was exacerbated by mutated tau. In vitro studies reported deleterious 
effect of Aβ oligomers on both axonal transport and tau physiological properties 
[85-87]. Moreover, a convergent role of PS and tau in axonal transport and 
neuronal survival and function was proposed [88]. Misregulation of both genes in 
the same mouse accelerated neurodegeneration and tau phosphorylation, at least 
at peripheral level. PS1 FAD-mutations were associated with increase in kinesin1 
phosphorylation by GSK-3K followed by kinesin1-vescicles complex disassembling 
and kinesin1 degradation [89], leading to FAT impairment of specific membrane 
proteins, such as APP and TrkR, neurothophins and mitochondria. Transport 
alterations might arise not only as a consequence of molecular transporters defects 
but also from alterations in the actin cytoskeleton. Recently, a growing body of 
evidence has brought to light an active role of Aβ in cytoskeletal abnormalities [90]. 
According to the results, Aβ42 might induce the formation of rod-shaped actin 
bundles (rods) that would be able to sequester the phosphorylated form of tau [91]. 
Blockage and inhibition of neuritic transport were associated with axonal swelling 
where the local accumulation of APP, Aβ and vesicles lead to synaptic failure and 
neurodegeneration [92, 93]. 
3.2.2 Synaptic dysfunction 
It has been demonstrated that synapses loss precede neuronal degeneration in AD 
[94, 95]. Synapses damage is experimentally associated with loss of synaptic 
marker or with loss of synaptic plasticity. Synaptic markers can be divided in (i) 
presynaptic, such as synaptophysin, an indicator of the presynaptic terminal 
density, and (ii) postsynaptic, such as AMPA and NMDA receptors (AMPAR and 
NMDAR, respectively), indices of the dendritic spines density. Long term 
potentiation (LTP) and depression (LTD) are forms of long-term plasticity while 
paired-pulse facilitation (PPF) and depression (PPD) are forms of short-term 
plasticity and have been used to monitor the synaptic changes.  
LTP observed in CA1 region of hippocampus is only one of the forms of long term 
synaptic plasticity depending on functionality of the medial temporal lobe and 
known to be impaired in MCI subjects [96]. Synaptic plasticity is related to the 
cellular changes involved in memory formation and, being its impairment involved 
in the precocious AD phases, the understanding of its biological mechanisms could 
supply new therapeutic targets.  
APPPS1-21 mice resulted in an age-related CA1 LTP impairment, probably 
dependent on plaque formation, and in a PPF impairment at 15-months of age [97]. 
In these mice, hippocampal Aβ deposits emerging at 4 months were surrounded by 
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synaptophysin-positive dystrophic terminals and boutons and hyperphosphorylated 
tau-positive neuritic structures [98]. Before plaque deposition, old Tg2576 [99] and 
homozygous APP/PS1KI (with 2 knock-in PS1 alleles) [100] exhibited hippocampal 
LTP impairment together with impaired performance in working memory tasks. In 
Tg2576 mice these deficits were probably related to a decline in functional synaptic 
plasticity because synaptic transmission was maintained (minimal or no loss of 
hippocampal presynaptic and postsynaptic structures were identified) [24, 99]. 
Another study applying the same model (Tg2576) reported opposite results namely 
normal LTP and synaptic transmission impairment [101]. In APP/PS1KI 6-months 
old, the levels of pre and postsynaptic markers considered were significantly 
decreased in the synaptosome-enriched protein fraction indicating a synaptic 
transmission damage. APP/PS1KI was a suitable model to study early Aβ peptides 
effects on brain cell populations in so far Aβ42 comprised 85% of total Aβ, 
consisting of full length and heterogeneous N-terminal modified variants. These 
mice exhibited hippocampal atrophy [100] and severe learning deficits [102] 
already at the age of 6 months and neuronal loss pattern matched better with 
oligomers distribution rather than with plaques. Since APP products were 
detectable already at 2 months, the authors speculated the existence of a narrow 
period for the onset of the synaptotoxic effects. Interestingly, hemyzygous 
APP/PS1KI (with 1 knock-in PS1 allele) and PS1KI mice exhibited normal LTP, 
maybe related to low expression of enodogenous murine PS1, considering that PS 
FAD mutations were able to produce synaptic plasticity impairment [103]. Old 
PS2APP showed significantly enhanced PPD and no difference in LTP when 
compared with WT [26]. In contrast, no difference in the levels of hippocampal LTP 
and basal transmission between Tg and WT was found in APPsw/PS1A246E mice 
[104] suggesting the presence of an intact machinery for induction and expression 
of LTP at CA1 synapses in this model. The involvement of Aβ in synaptic 
degeneration was further confirmed by a new mouse model of oligomer-induced 
pathology lacking plaques until 24 months of age [105] and by a study where the 
treatment with a γ-secretase inhibitor improved synaptic function and plasticity in 
Tg2576 within days [106].  
In htau mice, a mouse model in which the mouse tau gene was replaced by a non-
mutated human tau gene, an age-dependent learning impairment dependent on 
disruption of synaptic functions was shown, concomitant to tau pathology and not 
to neuronal death [107]. PS19 mice, a model with mutated tau, showed synaptic 
pathology in the CA1 hippocampal region at 6 months of age (before neuronal loss 
and NFT formation) consisting in basal synaptic transmission impairment, 
presynaptic disfunction and LTP deterioration [108]. In another study, two new 
inducible tau mouse models were created using a “pro-aggregation” and an “anti-
aggregation” sequence [109]. In both mutants, mutated Tau induced missorting of 
tau in somatodendritic compartments and bound equally well to microtubules. Only 
the pro-aggregation model showed tau aggregation proceeding to a pre-tangle 
oligomeric state. The decline in number of synapses was most pronounced with the 
pro-aggregation form and the authors concluded that synapses loss is related to 
aggregation of tau rather than to its missorting. All Tau-induced pre-tangle changes 
were reversible when the expression of Tau was turned off.  
 11 
An LTP age-dependent reduction correlating with intraneuronal Aβ was revealed in 
CA1 region of the hippocampus in older 3xTg compared to WT. The PPF was 
unaffected (68). Despite this hippocampal synaptic plasticity impairment occurring 
before plaques and NFTs development, the synaptic vesicle recycling was not 
affected [110] even if morphological changes were reported [111]. In another 3xTg 
the reduction in both soluble Aβ and tau levels, but not Aβ alone, was followed 
after immunotherapy by cognitive function improvement suggesting a synergistic 
actions of Aβ and tau in cognitive decline [112].  
Thus, both tau and Aβ seem to be directly involved in synaptic decay but the exact 
cellular mechanisms is unknown. Aβ oligomers, rather than plaques [113], 
monomers or fibrilles, block LTP [114] and reduce the density of dendritic spines 
and numbers of electrophysiologically active synapses [115]. Several mechanisms 
of oligomers toxicity have been proposed including a possible interference with the 
cholinergic signalling pathway [116-119] and/or alteration of the glutammatergic 
transmission [120-123] and/or, even the damaging of the calcium balance (88), 
essential for LTP induction. The role of tau in this scenario is not clear. In reality, in 
AD patients tau accumulates in the somatodendritic compartment and 
neurofibrillary tau deposits correlates better than Aβ with neuronal loss [124] and 
with the severity of the dementia [125]. 
3.3 Imaging markers  
MRI is a non invasive technique that permits the quantification of the structural 
profile in vivo and in vitro and has been widely used to characterize AD disease in 
human. Advanced in this field make MRI applicable in mice as well as in humans 
allowing comparative studies among different Tg and translatable studies between 
human and mice throughout the progression of the disease.  
3.3.1 Structural outcomes 
3.3.1.1 Structural MRI 
Neuroimaging markers are among the most promising candidates to track disease 
progression [126]. Indeed, whole brain and hippocampal atrophy are two of the 
most validated surrogate outcomes for clinical trials [126]. Hippocampal atrophy 
detected by MRI has recently been accepted by European Medicined Agency 
(EMA) for use in clinical trials in pre-dementia stage of AD 
(EMA/CHMP/SAWP/809208/2011). AD is characterized by grey matter loss in 
specific regions such as hippocampus, lateral and medial parietal, posterior 
cingulate and lateral temporal cortices, useful for defining the pathology and 
tracking its progression [127].  
Atrophy in mouse models using imaging techniques is difficult to identify, both 
because in many models is not present or is not enough extensive to involve the 
whole structure volume and because often the volumes differences are related to 
development defects and not to amyloid pathology. For these reasons, each Tg 
has a specific structural alteration signature. Two approaches are generally used to 
calculate the anatomy structures volumes, one relies on manual segmentation and 
the other take advantage of automatic tools. The first one is more accurate but is 
time-consuming, operator-dependent and measures only few regions of interested 
(ROI), the second considered much more anatomical regions independently of a 
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priori hypothesis but its use is challenging because of brain variations. Mice 
carrying a single APP mutation were analyzed applying the manual ROI definition 
approach with different results. PDAPP showed hippocampal volume deficits 
probably due to a continuous hippocampal development in controls that did not 
happen in Tg [128]. In APP-Au model, characterized by intracellular Aβ 
accumulation in absence of plaques, volume reduction in the whole brain and in 
the cortex but not in the hippocampus were observed [129]. PS2APP did not show 
any volumetric difference in whole brain and ventricles [130]. In APPPS1 brain size 
reduction and CSF volume increase in old mice were detected but atrophy 
concerned mainly posterior brain areas not usually involved in AD [25]. To 
overcome the limitations of manual ROI approach, non-biased automated methods 
have been introduced. Brain volume increase is reported in APP/PS1 [131] and 
TASTPM [132]. In the former the hippocampus is smaller than in control, whereas 
in TASTPM the hippocampal formation enlarges. In general, MRI imaging is useful 
to differentiate Tg and controls but the hippocampal volume deficits detected are 
ascribable to development rather than pathological factors. Anyway, a mouse 
model where the disease started after the brain was fully mature was analyzed 
immediately before and shortly after the onset of amyloid formation [133]. These 
mice were created using a system that permit the temporal control of the mutated 
APP expression through the administration of a drug. Drug removal, and 
consequent transgene expression, was performed after 6 weeks of life. The 
authors found volume reduction in whole brain, cortex and hippocampus before 
amyloid deposition. Moreover, volumetric losses identified in regions not normally 
considered because not directly AD-associated, predicted locations of amyloid 
formations at later stages of the disease. This model reproduce many futures of the 
human disease and could be good to study pre- and post-amyloid volumetric 
changes. This proves the enormous potentiality of automated methods showing 
unexpected sites of degeneration and allowing the study of their role and their 
connections in the progression of the pathology. Figure 2 summarized the 
comparison of the structural markers results between human and mice.  
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Figure 2. Structural markers in humans and mice. In humans, grey matter loss 
in regions such as hippocampus (hp), cortices (ctx) and whole brain (WB) is useful 
for defining the AD pathology and tracking its progression. The brain morphological 
alteration of Tg mice are linked with neurodevelopmental rather than 
neurodegenerative factors. Indeed, each Tg has a specific structural alteration 
signature and are described one by one. Volume decrease and increase are 
represented in red and blue colours respectively while no differences between Tg 
and controls are illustrated in green. Continuous line represents whole brain (WB), 
dotted line only posterior brain. The only mouse model exhibiting hippocampal 
volume decrease and deficits in cortical volume detected using MRI is the Inducible 
APPswe/Ind, where pathology develops when the brain has reached fully maturity. 
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3.3.1.2 Diffusion Tensor Imaging (DTI)  
DTI is a quantitative MRI technique that allows the description of tissue 
microstructures exploiting the diffusion properties of water and the detection of 
white matter lesions. DTI parameters commonly obtained from DTI image analysis 
are fractional or relative anisotropy (FA or RA, respectively), which are measures of 
tissue integrity, mean diffusivity (MD), trace and apparent diffusion coefficient 
(ADC= Trace/3), which evaluate the total water diffusion, axial (λII) and radial (λ┴) 
diffusivity, indices of axonal injury and demyelination, respectively.  
In human, white matter lesions such as atrophy of the corpus callosum as well as 
MD and anisotropy alterations are higher in AD than in healthy subjects [134] and 
DTI parameters changes in the medial temporal lobe (parahippocampus [135] and 
posterior cingulum [136]) and hippocampus [137] seem promising markers for 
disease progression.  
Analysis of different white matter tracts of PDAPP mice revealed significant 
decrease in RA and increase in Trace and radial diffusivity in 15-month-old Tg 
[138]. Despite Aβ was detected in cortex, hippocampus and, to a lesser extent, 
within the external capsule of old Tg no correlation between RA values and Aβ load 
was found. Tg2576 was examined considering also several grey matter regions 
[139]. When Aβ deposition was known to increase, differences in DTI indices 
values became detectable, especially in the corpus callosum. A correlation test 
between Aβ load and DTI indices was not performed because of the limited 
number of mice considered in the study. However, a positive relation between 
cortex trace and Aβ load was observed. Analysis of TgCRND8 applying diffusion-
weighted imaging (DWI) did not find significant changes in ADC in all the grey 
matter regions considered [140]. One explanation could be the different and less 
informative technique used instead of DTI. Future studies with automated approach 
could reveal unexpected group differences in white and grey matter diffusion 
abnormalities impossible to detect with manual procedure. 
Several similarities has been found between human and mice, specially in white 
matter regions. The difficulty to define valid DTI outcomes begin from human field 
and rely on the lack of longitudinal studies, the impossibility to correlate DTI 
parameters changes to histological sections and the absence of a complete 
agreement between all the literature reports. In this scenario mouse models 
become essential given that histological evaluation, hence Aβ and DTI indices 
variation correlation, is possible.  
3.3.2 Functional or metabolic outcomes 
Cerebral metabolism and blood perfusion correlate better than Aβ load to cognitive 
status in AD patients [141]. Glucose uptake can be evaluated with FDG 
autoradiography or PET, while blood perfusion or metabolites concentration 
analyses with MRI.  
3.3.2.1 Glucose uptake 
FDG uptake is believed to reflect synaptic activity [142]. Human PET studies in AD 
patients found progressive glucose uptake impairment in the hippocampus, 
followed by fronto-temporal (FT) and posterior cingulate cortices (PCC) [143]. 
Cerebral metabolism decline in the entorhinal cortex and hippocampus can 
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discriminate MCI patients that will convert to AD from MCI that will not convert 
[144].  
An age-dependent increase of FDG uptake was reported in the cortex and 
hippocampus of APPPS1 [145]. Other two FDG-PET studies were performed in 
Tg2576. One did not detect appreciable differences between Tg and control [146]. 
The other revealed an abnormal hypermetabolism at least until 7 months of age 
[147], a completely different situation from the human condition. These data 
suggest that Tg2576 are not a reliable model to study neuronal metabolism and 
that PET in vivo applications in mice are probably still limited.  
FDG autoradiography, with its higher resolution, is a valuable alternative to PET. 
This technique in aged PDAPP showed a significant reduction in whole brain and 
PCC FDG-uptake when compared with young Tg and age-matched controls [148]. 
This progressive decline in PDAPP was not linear during aging but, noteworthy, 
PCC metabolic deficits appeared before amyloid deposition and seemed to be 
related to memory deficits [149]. Morphological analysis had indicated important 
developmental defects in these mice, which could confound the metabolic results. 
Mice without severe cerebral alterations were evaluated. Analysis of old PSAPP 
demonstrated reduced FDG uptake in PCC and retrosplenial cingulate gyrus [150] 
but a longitudinal study supporting the progressive reduction has not yet been 
performed. FDG-autoradiography in a triple Tg mice (3xTg), carrying plaque and 
tangles, showed hypometabolism in all measured regions, including cortical and 
subcortical gray matter, cerebellum and brainstem [151].  
3.3.2.2 Brain perfusion 
Brain perfusion is a marker of neuronal activity. Cerebral blood volume (CBV) and 
cerebral blood flow (CBF) assessment based on magnetic resonance, provide 
information similar to FDG-PET in patients [152]. Cerebral hypo-perfusion on single 
photon emission tomography (SPET) in the posterior temporo-parietal lobes, is a 
consistent finding in AD patients [153] and has been correlated with Braak 
pathological stages [153] and with cerebrospinal fluid (CSF) biomarkers [154].  
Because of the small size of the mouse brain, the discrimination of brain regions 
(ROI) is difficult. Anyway, an interesting cross-species study between humans and 
a mouse model expressing a double APP mutation showed a similar pattern of 
CBV defects in the hippocampal formation of both [155]. Prominent CBV 
dysfunction in the entorhinal cortex in mice was rescued by chronic administration 
of a drug that reduced Aβ-related neurotoxicity. These results point out that CBV is 
a functional imaging marker able to detect Aβ-hippocampal dysfunction even in the 
absence of cell death or NFT. Reduced blood perfusion was demonstrated also in 
the cortex of APPxPS1-KI, a model featuring, among others, hippocampal cell loss 
[156]. Whether this cerebral blood reduction was due to cell loss and/or to cerebral 
abnormalities still has to be explored, however similar findings were reported in the 
cortex of single APP transgenic mice (Tg2576) [157] where the cell loss has not 
been described. Superoxide dismutase 2 (SOD-2) co-expression conferred these 
mice protection against vascular and neuronal deficits suggesting a possible 
important role of reactive oxygen species in Aβ neurotoxicity. A study in PS2APP 
found reduced blood supply in the occipital cortex compared to controls, already at 
an early age [158] but these results were not confirmed by another group [28]. The 
reason is probably related to the different genotype of the two models, the former 
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being homozygote and the latter heterozygote for PS2APP. Perfusion deficit was 
described also in the dorsal cortical area of TauPS2APP at the age of 15 months 
when compared to Tau single mutant [28] and in the hippocampus of another 3xTg 
[159]. Figure 3 summarizes the comparison of the functional markers results 
between humans and mice.  
 
 
Figure 3. Functional and metabolic markers of preclinical AD in humans and 
homologous markers in Tg mice. Neuronal functionality is compromised many 
years before the appearance of clinical symptoms. Human studies found 
progressive functional impairment in the hippocampus (hp), posterior cingulate 
cortex (PCC), entorhinal cortex (ent) and temporo-parietal cortex (TP) of AD 
patients. The same areas were investigated in transgenic mice. 
Top: Functional markers of preclinical AD in humans. Middle: Mice strains where 
functional markers homologous to humans have been identified (e.g. metabolic 
deficits in the hippocampus of J20 and 3xTg mice). Bottom: Mice strains where the 
same markers have been evaluated giving opposite results in comparison with 
humans. Markers decrease and increase are represented with red and blue colours 
respectively. 
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3.3.2.3 Spectroscopy (MRS) 
MRS identifies and tracks neurochemical changes of biochemical metabolites such 
as N-acetylaspartate (NAA) or myo-inositol (mIns). NAA is mainly located in 
neuronal cells and its reduction had generally been accepted as an indicator of 
neuronal dysfunctions. mIns is primarily present in the glial cells and elevation of its 
levels is associated to glial proliferation and inflammation. Compared to the NAA 
and mls, choline (Cho), another compound considered in MRS analysis is present 
at low concentrations in brain tissue. Increased levels of Cho in AD has been 
correlated to the chronic deficiency in acetylcholine production and 
neurodegeneration.  
Human spectroscopy studies showed decrease in NAA in the posterior cingulate 
gyrus and medial temporal lobes of people with MCI as much as in patients with 
AD [160] and increase in mIns in the parietal lobes of MCI and mild AD [161].  
A reduction in NAA and glutamate (Glu, another neuronal marker) was obtained in 
the cortex and hippocampus of aged APP-PS1 [162, 163] and their levels 
correlated with increasing brain amyloidosis. No differences in mIns between Tg 
and controls was reported [162] until 400 days of age when an increase was 
detected [163]. Stable mIns levels, decrease of the NAA and increase of choline 
(Cho) and taurine intensity were reported in the cortex of old Tg2576 [164]. Rodent 
taurine might perform a role similar to human mIns. PS2APP [130] revealed stable 
NAA and Glu during the first 12 months of age that significantly decrease at 24 
months. An increase in mIns was detected in old Tg but the variability was too high 
to be statistically significant. Limiting factors in the translational application of MRS 
are the difficult to obtain good spectra in mice due to the small murine brain size 
and the cross-species metabolic profile differences.  
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3.4 Part I: animal imaging study goals  
We limits our investigation to the structural outcomes because definition of 
functional acquisition and analysis protocols is still ongoing. We analyzed in details 
morphometric and diffusion changes of three different mouse models of AD such 
as TASTPM, TauPS2APP, PDAPP and WT at 5 ages using different MRI 
techniques. The morphometric data evaluated includes subcortical, ventricular and 
intracranial volumes as well as entorhinal thickness while the diffusion parameters 
were FA, MD, λII and λ┴  in white and grey matter regions. 
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3.5 Materials and Methods 
3.5.1 Animals 
Experiments were conducted with PDAPP, TASTPM, TauPS2APP mutant mice 
(see Table 1 in the Introduction for genetic details and Fig. 1b for phenotypic 
features) and non transgenic C57/BL6 (WT). Mice were longitudinally or cross-
sectionally followed from 3 to 22 months (for number per age, gender and study 
design, please refer to table 2). All mice were housed under a 12 hour light and 12 
hour dark and fed with standard laboratory chow and water ad libitum. 
 
 
Table 2. List of the transgenic mice and their respective controls included in this 
study, specified by animals per age, gender and study design. Abbreviations: CS= 
cross-sectional; LG= longitudinal. 
3.5.2 MRI animal preparation 
The animals were initially anesthetized with isoflurane (5% for induction and 1% 
during the set-up) in a mixture of O2 (30%) and NO2 (70%) gases, delivered to the 
nose cone for spontaneous respiration throughout the experiment. Stereotaxic hear 
bars were used to minimize movements during the imaging acquisition. 
Temperature was maintained at ~37°C by a feedback-c ontrolled, water circulated 
heating craddle. 
3.5.3 MRI acquisitions 
MRI was performed using a 7T small bore animal Scanner (Bruker Biospec, 
Ettlingen, Germany). Two actively coupled radio frequency (RF) coils were used: a 
volume coil with a 7.2 cm diameter used as the transmitter and a 1 cm surface coil 
diameter positioned on the top of the animal’s head as the receiver. The 
ParaVision 5.1 software interface (Bruker BioSpin, Ettlingen, Germany) was also 
used for data acquisition. 
A 3D RARE T2-weighted sequence allowed the acquisition of 102 sagittal slices 
with 147 µm thickness, which covered the whole mouse brain volume. The 
morphological images were obtained with an in-plane resolution of 117 x 147µm 
(matrix 256 x 102 and a Field of View (FOV)= 3 x 1.5 cm); repetition time 
(TR)=2500 ms, echo time (TE)=10 ms and a RARE factor of 16, for 1 average.  
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The diffusion-weighted acquisitions were gained using DTI EPI sequence which 
covered the whole brain except for the cerebellum. The diffusion-weighted images 
were acquired with matrix 140 x 140, FOV= 2 x 2 cm, TR= 3000 ms, TE= 36 ms, 
slice thickness 1 mm, b value= 800 s/mm2, one b0 image, 19 gradient directions 
and 4 averages.  
For T2 measurements a multislice multiecho sequence was used with the following 
parameters: 20 TE equally separated  by 11 ms, TR = 2500 ms, FOV = 2 x 2 cm2, 
matrix 256 x 256, slice thickness = 1 mm, acquisition time = 8 min. 
3.5.4 Data post-processing 
3.5.4.1 Volumetric data analysis 
The volume measurement of structural MRI images were obtained using a Java-
based  custom made software. Regions of interest (ROIs) were manually drawn by 
a trained expert and traced on the images for quantitative comparison of the brain 
atrophy of different regions. For each animal the ROIs were chosen following the 
definition of mice brain structures in the Paxinos’ atlases [165]. 
We studied the cortex, the hippocampus, the caudate-putamen, the olfactory bulb, 
the ventricular system, the whole brain and the total intracranial volume (Fig 4). 
The cortex was divided into frontal cortex (from Bregma 3.20 mm to Bregma 
1.54mm) and the rest of the cortex. Data from all the animals were obtained by 
averaging the values calculated multiplying the total ROI area for the slice 
thickness. We manually traced the total intracranial volume, the whole brain, the 
hippocampus and the olfactory bulb on the sagittal view; the other regions were 
traced on the coronal view.  
 
Fig 4. Some examples of sagittal (first row and bottom left) and coronal (second 
row middle and right) images of a young WT are shown with overlay of the masks 
used for the manual volume segmentation. Abbreviations: Cau-Put= caudate-
putamen, Hp= hippocampus, OB= olfactory bulb, ctx= cortex (except the frontal), 
Vent= lateral, third and fourth ventricles, WB= whole brain, ICV= intracranial 
volume. 
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3.5.4.2 Diffusion data analysis: estimation of structural connectivity 
measures 
3.5.4.2.1 Tract-Based Spatial Statistics (TBSS) 
In order to reliably process the FA images, we developed a processing pipeline 
based on a modified version of the user-independent method TBSS. The 
processing stream consists in the following steps: (i) FA template computation by 
iterative affine registration of the individual FA images; (ii) individual FA maps 
projection into the reference space of the template; (iii) skeletonization of the 
template and choice of a threshold value (usually 0.2); (iv) group-wise voxel-by-
voxel comparison of the FA distributions; (v) analysis of the other DTI indices 
maps. The statistical significance was assessed at p<0.05 corrected by multiple 
comparisons. 
3.5.4.2.2 ROI-based analysis 
Each diffusion-weighted series was used to compute the six independent 
components of the diffusion tensor. The three eigenvalues (λ1, λ2, λ3) and the 
eigenvectors of the resulting tensor map were derived by matrix diagonalization 
[79]). The DTI indices FA, MD (10-3 mm2/s), λII  (10-3 mm2/s) and λ┴  (10-3 mm2/s) 
are defined by the following equations: 
 
   
  
 
  
The FA, MD, λII and λ┴  maps were obtained using the FMRIB Software Library 
(FSL, University of Oxford, UK). ROIs were manually drawn by a trained expert and 
traced on the the coronal view of the colour coded map and using a mouse brain 
atlas [165] as reference. For the white matter structures we studied corpus 
callosum, anterior capsule, external capsule, cerebral peduncle, fimbria and 
internal capsule. For the grey matter we focused on hippocampus, frontal cortex, 
thalamus, caudate-putamen and olfactory bulb regions (Fig. 5).   
 
(1) 
(4) 
(3) 
(2) 
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Fig 5. Examples of coronal color-coded images of a young WT are shown with the 
overlay of the masks used for the manual diffusion quantification (black 
background) and 3D masks visualization (grey background). Abbreviations: cc= 
corpus callosum, ac= anterior commissure, cc= corpus callosum, cp= cerebral 
peduncle, ec= external capsule, fi= fimbria, int= internal capsule,  Cau-Put= 
caudate-putamen, hp= hippocampus, OB= olfactory bulb, Frontal ctx= frontal 
cortex, Thal= thalamus, PIR= piriform cortex. 
 
3.5.4.3 Entorhinal cortex thickness measurement  
The thickness of the entorhinal cortex was measured in WT and Tg mice to identify 
structural differences. We chose a reference image between all the coronal 
acquisition. Then we registered all the other images to the reference one in order to 
avoid bias due to bad head positioning during the acquisition. For the image 
registration we used FLIRT (FMRIB's Linear Image Registration Tool), a fully 
automated robust and accurate tool for linear (affine) intra- and inter-modal brain 
image registration. We used a 3D to 3D rigid body registration with 6 degree of 
freedom. 9 coronal slices were selected at the level between Bregma -2.75 mm 
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and Bregma -3.80 mm based on mouse brain atlases (Paxinos and Franklin, 2003; 
Paxinos et al., 2006), and the thickness was measured below the rhinal fissure 
[166] (Fig. 6).  The measures were repeated 6 times (3 for the left and 3 for the 
right hemisphere) by a trained expert and the values were averaged to get the final 
values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. Entorhinal cortex (ERC) thickness definition shown on a coronal image 
of a WT mouse. Abbreviation: rf = rhinal fissure. 
3.5.5 Histology and immunohistochemistry 
A subset of mice was deeply anestethized with equitesin and was transcardially 
perfused with 0.1 M phosphate-buffered saline (PBS), pH 7.4 for histological 
analysis. The brains were than removed and postfixed for 2 h at 4°C in 4% 
paraformaldehyde. In order to cryoprotect the tissues, brains were immersed in 
20% sucrose at 4C overnight (o/n) and then frozen. Sagittal sections were 
prepared using a Leica cryostat using a slice thickness of 20 µm.  Amyloid plaques 
deposition was detected using 6E10 antibody (1:500; Signet, Dedham, MA), 
astrocytes with GFAP antibody (1:2500; Chemicom, Billerica, MA), and microglia 
with Cd11b antibody (1:1000; BD, Italy) and myelinated axons with gold chloride 
staining (Sigma; Italy). Slices were placed on gelatin-coated glass and dried 
overnight at room temperature (RT) for Gold Chloride staining while they were 
processed in 24-well plate (free-floating) for 6E10, GFAP and CD11b antibodies. 
Sections were then dehydratated using successively increasing percentages of 
ethanol, cleared with xylene and then covered with DPX. 
3.5.5.1 6E10, GFAP and Cd11b antibodies 
Prior to immunostaining, sections were washed 3 × 5 min in PBS and then 
incubated with 1% H2O2 (Sigma, St. Louis, MO) in order to quench endogenous 
peroxidase activity. 
Tissues were then incubated with blocking-permeabilizing solutions  containing  
10% normal goat serum (NGS) for plaque staining and also 0.4% Triton-X100 for 
glial cell staining. Incubation lasted 1 hour at RT. Following, sections were 
incubated with the appropriate antibody dilutions overnight on an orbital shaker at 
4°C. 
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The day after, brain slices were washed 3 × 5 min in PBS prior to incubation with 
the appropriate secondary antibody at a 1 : 200 dilution for 1 hr. Immediately after, 
sections were washed 3 × 5 minutes in PBS and were incubated in Vectastain ABC 
kit (Vector Labs, Burlingame, CA) in PBS for 1 hour.  
Sections were then washed 2 × 5 minutes in PBS and 1 x 5 minutes in Tris-
buffered saline (TBS) and developed with 3,3'-diaminobenzidine tetrahydrochloride 
(DAB, Sigma, St Louis, MO). For comparison across different ages, sections from 
animals of different ages were immunostained at the same time.  
3.5.5.2 Gold-chloride 
Sections were immersed in PBS containing 0.2% gold chloride (Sigma, St Louis, 
MO) for 14 hours. Tissues were then removed and washed twice for 10 minutes 
with PBS and once in 2.5% sodium thiosulfate anhydrous. 
3.5.6 Statistical analysis 
Analysis of the MRI and T2 data were conducted using GraphPad Prism 5 
software. The two-square root transformation was used to normalize the volumetric 
data. To compare volumes and DTI parameters among WT and Tg mice two-way 
ANOVA analysis followed by Hochberg post-hoc test was applied. Statistical 
significance was established as *P<.05; **<.01; ***<.001. Descriptive statistics 
were illustrated using means and standard deviation for each age/genotype 
group’s values and only significant differences between genotype are shown. 
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3.6 Results 
A comparison of the changes in time across these mouse models was also 
evaluated. In particular, we examined the history of structural and diffusion brain 
changes of TASTPM, TauPS2APP, PDAPP, C57/BL6 mice using in vivo MRI. For 
a quantitative assessment of genotype differences, the subcortical, cortical, 
ventricle, intracranial volumes and white and grey matter diffusion parameters have 
been examined for each mouse. TauPS2APP and their controls were followed 
longitudinally while the others, due to the small number of animals, were followed 
cross-sectionally. The ages considered were five (3, 9, 13, 18 and 22 months).  
3.6.1 TASTPM  
3.6.1.1 Morphometry results  
Table 3 presents the group mean volumetric and ERC thickness results for both 
WT and TASTPM mice computed from manual segmentation. When comparing 
males to females, we found no significant differences in the measures detected 
and the data reported are the average of the entire group.  
Total intracranial and whole brain volumes increased in both groups but were 
greater in TASTPM. Because the regional volumes did not linearly change with the 
whole brain, to avoid over-evaluations of the differences we did not normalize the 
regional volumes by the respective TIV considering the volumes in absolute terms. 
Cortical and subcortical volumes decreased progressively with age in TASPM while 
were altered a little in WT (Table 3 and Fig. 7). Caudate-putamen and frontal cortex 
were similar at 4 months, but at 9 months were significantly smaller in TASTPM 
than in WT; indeed, transgenexage interactions were strongly significant for both 
regions (p< 0.001 and 0.01, respectively). Same trend but opposite direction for the 
ventricles (interaction p< 0.001). In TASTPM, the olfactory bulb started to decrease 
later than 13 months and continued until 22 (interaction p value< 0.001). The 
hippocampus and the rest of the cortex were significantly smaller in TASTPM when 
compared with WT at all the ages considered. Anyway, a significant transgenexage 
interaction was detected (p< 0.05 and 0.001, respectively). 
The ERC thickness decreased in relation to age only in TASTPM starting at the 
age of 9 months (interaction p< 0.0001).   
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Table 3. Comparison between TASTPM and WT volume and thickness 
estimations. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes and thickness obtained from the manual segmentation. 
The ERC statistics refer to two-way ANOVA, **p<.01; ***p<.001 after Hochberg's 
correction. Abbreviations: Cau-Put= caudate-putamen, Hp= hippocampus, OB= 
olfactory bulb, Fron ctx= frontal cortex, ctx= rest of the cortex, Vent= lateral, third 
and fourth ventricles, WB= whole brain, ICV= intracranial volume, ERC= entorhinal 
cortex. 
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Fig 7. Comparison between TASTPM and WT normalized volumes across 
structures. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes derived from the manual segmentation. Axis y reported 
square root values. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's 
correction. Interaction p-values were also shown. The abbreviations were the same 
of Table 3. 
 
3.6.1.2 Diffusion results  
Typical T2-weighted images, FA maps and colour coded FA of TASTPM and WT 
brains are showed in Fig 8. 
 
 
 
Fig 8. Representative T2-weighted images, FA maps and colour-coded FA 
from one coronal slice of young TASTPM and age-matched control. 
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The TBSS comparison between TASTPM and WT was done only considering mice 
of 3, 13 and 22 months old. This analysis revealed changes in DTI parameters of 
several regions of transgenic mice. FA was significantly lower (p<0.05) in corpus 
callosum, external capsule, fimbria, cerebral peduncle and internal capsule of older 
TASTPM when compared to their age-matched controls (Fig 9, top). Viceversa, 
radial diffusivity was higher in external capsule, corpus callosum and fimbria of 
older Tg mice than in age-matched WT (Fig 9, bottom).  
 
 
 
Fig 9. Automated FA and λ┴ maps comparisons between older TASTPM and 
age-matched controls. Coronal brain images overlaid with the skeleton (green) 
and with the TBSS results. Data showed significantly (p< .05) lower (red-yellow) FA 
and higher (light-blue) λ┴ values in external capsule, corpus callosum, fimbria and 
cerebral peduncle of TASTPM. 
 
Hand-drawn approach was used to perform quantitative analysis of DTI indices in 
several white (Table 4 a and b) and grey matter regions (Table 4c). In general, DTI 
parameters changed progressively with age only in several structures of TASTPM 
while remained stable or was altered a little in WT (Table 4). A significant age-
dependent FA, reduction starting at 13 months, was seen in the corpus callosum 
and anterior commissure (Fig. 10) (transgenexage p< 0.0001 for both) of TASTPM. 
A concomitant reduction of axial diffusivity (interaction p< 0.0001 for both) and an 
increment of radial diffusivity (ac interaction p< 0.0001 and cc, p= 0.0002) was also 
seen (Fig. 10). FA decline in cerebral peduncle and cingulum started when 
TASTPM were 18 months old (cp interaction p< 0.0001 and cing, p= 0.001) and in 
external capsule and fimbria when were 22 (ec interaction p= 0.0025 and fi p= 
0.0007). In the caudate-putamen, thalamus and olfactory bulb we detected an 
increase in MD at 22 months (interaction p= 0.0034, 0.0069 and 0.034, 
respectively).  
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Table 4. DTI indices of the white (a, b) and grey (c) regions of interest. MD, λII and λ┴ are expressed as 10-3mm2/s. Two-
way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. Interaction p-values are shown in the transgene x age 
column. Abbreviations: FA= fractional anisotropy, MD= mean diffusivity, λII= axial diffusivity, λ┴= radial diffusivity, cc= corpus 
callosum, ac= anterior commissure, cp= cerebral peduncle, cing= cingulum, int= internal capsule, ec= external capsule, fi= 
fimbria, Cau-Put= caudate-putamen, Hp= hippocampus, OB= olfactory bulb, Thal= thalamus, ns= non-significant. 
c 
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Fig 10. DTI indices in the anterior commisure (ac) and corpus callosum (cc) 
of TASTPM and age-matched WT. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 
after Hochberg's correction. Interaction p-values are also shown. 
 
3.6.1.3 Histology 
At least five mice from all ages were stained for Aβ deposits, myelinated axons, 
microglia and astrocytes activation. 
As expected, the 3 months old TASTPM tissues did not show the Aβ deposits. 
However, around 9 months of age, TASTPM began to exhibit Aβ pathology in 
cortex, corpus callosum, hippocampus and thalamus. Plaques increased with age 
in number and size (Fig. 11) and covered all brain in the older transgenic. The 
majority of the plaques was surrounded by activated glia and GFAP-postive 
astrocytes (Fig. 12 a and b, respectively), clear signs of neuroinflammation. Finally, 
fibers and white matter organization were reduced in corpus callosum and striatum 
of TASTPM, from 13 months (Fig. 13).  
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Fig 11. A representative comparison of amyloid load among older WT and 
different ages of TASTPM. Sagittal slices were immunostained with the 6E10 
antibody. TASTPM Tg mice display Aβ deposits which became visible at 9 months 
and increased with age. Even if the majority of the amyloid burdens was in the grey 
matter, deposits in white matter were clearly evident (magnification 4x; scale bar, 
250 µm). Abbreviations: Cau-Put= caudate-putamen, Hp= hippocampus, ctx= 
cortex, cc= corpus callosum, Thal= thalamus. 
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Fig 12. A representative comparison of neuroinflammation among older WT 
and different ages of TASTPM. Sagittal slices were immunostained with Cd11b 
(a) and GFAP (b) antibodies. Microglial (arrow) and astrocytes (arrowhead) 
activation were observed when amyloid was present (magnification 4x; scale bar, 
250 µm). The abbreviations are the same of Fig 11. 
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Fig 13. A representative comparison of myelinated axons among older WT 
and different ages of TASTPM. Sagittal slices were stained with Gold chloride. A 
progressive white matter disorganization starting at 13 months is observable in 
TASTPM Tg mice (magnification 4x; scale bar, 250 µm). The abbreviations are the 
same of Fig 11. 
 
 
 
 
 
 
 
 
 37 
3.6.2 TAUPS2APP 
3.6.2.1 Morphometry results 
Table 5 shows the volumes and ERC thickness means for WT and TauPS2APP 
mice derived from manual segmentation. When comparing males to females, we 
found no significant differences in the measures detected and the data reported 
are the average of the entire group.  
Total intracranial and whole brain volumes were not affected by the transgene 
presence and had the same trend in both groups. As for TASTPM we used the 
absolute volumes and not the normalized data. Cortical and subcortical volumes 
changed progressively with age in transgenic mice in most of the regions 
considered while was altered a little only WT (Table 5 and Fig. 14). Caudate-
putamen, frontal cortex and the rest of the cortex were similar between WT and 
TauPS2APP at 4 months but at 9 months were significantly smaller in 
TauPS2APP; indeed, transgenexage interactions were highly significant for all 
(Cau-Put p-value< 0.001, Frontal ctx and ctx interaction p-value< 0.01). The 
hippocampus was significantly smaller in TauPS2APP when compared to WT at all 
the ages considered. Anyway, a significant transgenexage interaction was 
detected (p< 0.001).  
The entorhinal thickness was smaller in TauPS2APP at 4 months and decreased in 
relation to age only in TauPS2APP (interaction p< 0.0001).   
 
 
 
Table 5. Comparison between TauPS2APP and WT volume estimations 
across structures. Within-site group means and standard deviation (across mice 
and hemispheres) of volumes and thickness derived from the manual 
segmentation. The ERC statistics refered to two-way ANOVA, **p<.01; ***p<.001 
after Hochberg's correction. The abbreviations were the same of Table 3. 
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Fig 14. Comparison between TauPS2APP and WT normalized volume 
estimations across structures. Within-site group means and standard deviation 
(across mice and hemispheres) volumes derived from the manual segmentation. 
Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. 
Interaction p-values were also shown. The abbreviations were the same of Table 3. 
 
3.6.2.2 Diffusion results 
The TBSS comparison between TauPS2APP and WT was done only considering 
mice of 3, 13 and 22 months old. This analysis did not reveal any significant 
reduction or increment of FA in transgenic mice when compared to WT (data not 
shown).  
In general, quantitative DTI parameters were significantly different from the age-
matched controls only in several grey matters regions (Table 6). In the caudate-
putamen of TauPS2APP there was a significant difference in the FA values at 9 
and 13 months (p< 0.001). The hippocampus of transgenic mice showed higher 
MD at 18 months (p<0.01) while the thalamus smaller FA at 3 months (p<0.001).  
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Table 6. DTI indices of the grey regions of interest. MD is expressed as 10-
3mm2/s. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. 
Interaction p-values are shown in the transgene x age column. Abbreviations: Cau-
Put= caudate-putamen, Hp= hippocampus, Thal= thalamus, ns= non-significant. 
 
3.6.2.3 Histology 
After MRI acquisitions five older TauPS2APP and WT mice were sacrificed and 
stained for Aβ deposits, myelinated axons, microglia and astrocytes activation. 
Aβ deposits, although to a lesser extent than in TASTPM, can be seen in cortex, 
corpus callosum, hippocampus, caudate-putamen and thalamus of older Tg mice 
(Fig. 15). Also in TauPS2APP plaques were surrounded by activated glia and 
GFAP-postive astrocytes (Fig. 16 a and b, respectively). Finally, no obvious white 
matter pathology can be seen in the Tg brain (Fig. 17).  
 
 
Fig 15. A representative comparison of amyloid load among older mice. 
Sagittal slices were immunostained with the 6E10 antibody. Aβ deposits can be 
seen in corpus callosum, hippocampus, cortex, caudate-putamen and, to a lesser 
 40 
extent, in the thalamus (magnification 4x; scale bar, 250 µm). The abbreviations 
are the same of Fig 11. 
 
a 
 
 
b 
 
 
Fig 16. A representative comparison of neuroinflammation among older mice. 
Sagittal slices were immunostained with Cd11b (a) and GFAP (b) antibodies. Only 
older TauPS2APP exhibited glial (arrow) and astrocytes (arrowhead) activation 
(magnification 4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
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Fig 17. A representative comparison of myelinated axons among older mice. 
Sagittal slices were stained with Gold chloride. Any qualitative difference between 
TauPS2APP and WT can be appreciated (magnification 4x; scale bar, 250 µm). 
The abbreviations are the same of Fig 11. 
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3.6.3 PDAPP 
3.6.3.1 Morphometry results 
Table 7 presents the volumes and ERC thickness means for WT and PDAPP mice 
derived from manual drawn. All mice were males.  
Total intracranial and whole brain volumes were not affected by the transgene 
presence and had the same trend in both. As for TASTPM and TauPS2APP we 
used the absolute volumes and not the normalized data. Cortical and subcortical 
volumes changed progressively with age in Tg mice while were altered a little only 
WT (Table 7 and Fig. 18). Frontal cortex was similar between WT and TauPS2APP 
at 4 months but at 8 months started to increase in WT; anyway, transgenexage 
interactions were highly significant (p< 0.01). Caudate-Putamen and hippocampus 
were significantly smaller in PDAPP at 4 months. By the way, significant 
transgenexage interaction was detected (p< 0.01 and p< 0.001, respectively). 
When comparing PDAPP and WT in the remaining structures, we found no 
significant differences in volumetric values. 
The ERC thickness decreased in relation to age only in PDAPP from the age of 13 
months (interaction p< 0.01).   
 
 
 
Table 7. Comparison between PDAPP and WT volume estimations across 
structures. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes and thickness derived from the manual segmentation. 
The ERC statistics refer to two-way ANOVA, ***p<.001 after Hochberg's correction. 
The abbreviations were the same of Table 3. 
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Fig 18. Comparison between PDAPP and WT normalized volume estimations 
across structures. Within-site group means and standard deviation (across mice 
and hemispheres) of volumes derived from the manual segmentation. Two-way 
ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. Interaction p-
values were also shown. The abbreviations were the same of Table 3. 
 
3.6.3.2 Diffusion results 
The TBSS comparison between PDAPP and WT was done only considering mice 
of 3, 13 and 22 months old. This analysis did not reveal any significant reduction or 
increment of FA in transgenic mice when compared to WT (data not shown).  
In general, quantitative DTI parameters were almost the same among PDAPP and 
WT for all the ages and the structures considered. Significant differences were 
detected only in the FA and λII of corpus callosum and external capsule (Fig.19). 
The corpus callosum showed smaller values at 4 months (any interaction between 
age and transgene for FA was detected, for λII p< 0.0001), the external capsule 
began to reach significant differences at 9 for FA (interaction p= 0.0002) and 13 
months for λII (interaction p= 0.0052). No relevant results in grey matters regions 
were detected. 
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Fig 19. DTI indices in the corpus callosum (cc) and external capsule (ec) of 
PDAPP and age-matched WT. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after 
Hochberg's correction. Interaction p-values were also shown. 
 
3.6.3.3 Histology 
At least five mice from all ages were stained for Aβ deposits, myelinated axons, 
microglia and astrocytes activation. 
Few Aβ deposits can be seen only in the hippocampus of older transgenic mice 
(Fig. 20). Obvious neuroinflammation (Fig. 21) and white matter pathology did not 
affect transgenic brains (Fig. 22).  
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Fig 20. A representative comparison of amyloid load among older WT and 
different ages of PDAPP. Sagittal slices were immunostained with the 6E10 
antibody. Few Aβ deposits can be seen only in the hippocampus of older PDAPP 
(magnification 4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
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Fig 21. A representative comparison of neuroinflammation among older WT 
and different ages of PDAPP. Sagittal slices were immunostained with Cd11b (a) 
and GFAP (b) antibodies. No qualitative difference between TauPS2APP and WT 
can be appreciated (magnification 4x; scale bar, 250 µm). The abbreviations are 
the same of Fig 11. 
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Fig 22. A representative comparison of myelinated axons among older WT 
and different ages of PDAPP. Sagittal slices were stained with Gold chloride. No 
qualitative difference between PDAPP and WT can be appreciated (magnification 
4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
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3.7 Discussion 
In order to identify imaging markers of disease progression in mice we have 
characterized three different mouse models of AD. In this work we have analyzed 
in details structural changes and differences among TASTPM, TauPS2APP, 
PDAPP and WT using different MRI techniques. The examination was performed 
through 3D MRI to study brain regions volumes and entorhinal cortex thickness. 
Microstructural variations in white and grey matter regions were detected using 
DTI. 
At 9 months TASTPM mice shown cerebral plaque pathology consisting in 
widespread parenchymal deposits (Fig 10). Moreover, deficits in memory tasks 
were detected at 6 months (REF) indicating an initial decline of brain function at 
this age. Beside Aβ age-dependen accumulation, TauPS2APP triple transgenic 
mice are characterized also by neurofibrillary tangles, detectable at a very early 
age, starting at 4 months [28]. In PDAPP Aβ plaques, dystrophic neuritis and 
gliosis should appear around 8 months of age (REF) but our findings are in 
contrast with these results. Indeed we found poor Aβ deposits in absence of 
gliosis only in older mice. 
3.7.1 Brain structural outcome 
3.7.1.1 Genotype effect 
We found a progressive whole brain and TIV volume increases in TASTPM, 
PDAPP and age-matched control. In TASTPM brain growth was greater than in 
WT, indeed from 4 to 18 months the percentage of whole brain increment is 4.2 for 
WT and 9.4 for TASTPM. This could be explained by the strong Aβ load (Fig 9) 
associated with marked gliosis and astrocitosys (Fig 10a and b) which was present 
in TASTPM. In PDAPP and WT was equally around 10%. Brain growing is not 
surprising if we consider that rodent cranium can expand. Similar findings have 
been reported in another study regarding TASTPM [132] and in other double Tg 
models [25, 131, 162]. WT local volumes remained stable in time while changes 
were discovered in Tg mice. Volume reduction was observed in caudate-putamen 
and hippocampus of TASTPM, TauPS2APP and PDAPP, as in another transgenic 
models  [166] and in human AD patients [124, 167].  Reduced volume was also 
seen in frontal cortex of TASTPM and TauPS2APP. These data are supported by 
the previous observations of frontal cortex pathology involvement in other APP/PS1 
[25, 162] and in human patients [168, 169]. Reduction in size was also noticed in 
the olfactory bulb of TASTPM, in line with the olfactory dysfunction affecting AD 
patients [170]. As entorhinal cortex was smaller in AD patients than in healthy 
controls [171], as it is in TASTPM, TauPS2APP and PDAPP when compared with 
WT mice. Similar findings were reported also for rTg4510 [166].  
3.7.1.2 Genotype x age effect 
Regarding the interaction between age and transgene we found two distinct pattern 
of changes across Tg and WT. One pattern shown the same baseline size and 
volume reduction at the following ages. This is the case of caudate-putamen and 
frontal cortex of TASTPM and TauPS2APP, olfactory bulb of TASTPM, cortex of 
TauPS2APP and PDAPP. Same trend but opposite direction for ventricles in 
TASTPM. The other pattern resulted in lower volumes in transgenic already at 4 
months, such as for hippocampus of all strains and for caudate-putamen of 
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PDAPP. These latter findings supported the hypothesis proposed by Delatour [25] 
that some volume deficits are ascribable to development rather than pathological 
factors.  
Although the AD pathology is extensively shown in the thalamus, its manual 
volumetric assessment can not be performed due to the particular anatomy. For 
DTI study was different because the masks do not have to cover the entire 
structure but has just to be inside it. This should be overcome with the application 
of automatic voxel-by-voxel analysis.  
3.7.2 Brain Diffusion outcome 
3.7.2.1 White matter 
Besides volumetric estimations, we examined the presence of microstructural 
alterations in white and grey matter of transgenic mice as detected in MCI [134] 
and AD patients [135]. Significant results have been obtained especially in 
TASTPM. We used two different approaches, one relies on manual segmentation 
and the other take adventages of automatic tools. Manual segmentation is more 
accurate but is time-consuming, operator-dependent and measures only few ROI, 
while automated analysis considers much more anatomical regions independently 
of a priori hypothesis but its use is challenging because of brain variations. We 
found a strong agreement between results computed using the two methods in the 
biggest anatomical structures (cc, cp and ec) but not in the smaller ones (ac). This 
is probably because our image resolution is not optimal and wide slice could bring 
partial volumetric effects (presence of different structures in one voxel and possible 
wrong diffusion parameters evaluation) affecting the steps required for the skeleton 
creation. Higher resolution is necessary to reduce partial volume effects not only in 
small structures but also in regions neighboring grey matter or cerebrospinal fluid. 
Nevertheless, this is a useful method to rapidly and reproducibly apply a voxel wise 
analysis to screen DTI parameters differences in white matter regions between Tg 
mice and WT. Moreover it shows potential utility for the evaluation of possible 
future treatments in mice models of AD or other neurodegenerative pathologies. 
Manual segmentation demonstrated FA, λII reduction and λ┴ increment in the 
corpus callosum and anterior commissure in 13 months old TASTPM (Tab 4 and 
Fig 8), when strong amyloid pathology compared. This diffusion parameter 
modification have been associated with axonal disconnection, volume reduction 
[172] and myelin degradation of the axonal bundles [173]. Imaging data correspond 
to histological findings of fiber disorganization (Fig 11). Similar results have been 
reported for another APP/PS1 model where corpus callous and anterior 
commissure volume reduction, loss of axonal neurofilaments and myelin 
breakdown were extensively demonstrated [174]. Interestingly, these two fiber 
tracts showed significant alterations in other Tg mice, although at later ages [138, 
139] and in AD patients [175, 176]. White matter injury interested also all the other 
white matter regions considered but they occurred in advanced stage of pathology 
(Table 4). 
3.7.2.2 Grey matter 
Grey matter organization is more heterogeneous than white matter. Indeed grey 
matter structures such as hippocampus or caudate-putamen contains a larger 
number of cell bodies and less fibers. Hence, we reported only MD and FA values. 
Elevated MD values indicating brain tissue alterations in MCI patients were found 
in the left hippocampus [137] and were associated with a greater hazard of 
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progression to AD in amnestic MCI [177]. Despite the lower hippocampal volume of 
TASTPM and TauPS2APP relative to WT we found higher MD values at all ages 
but, as mentioned above, were probably related to neurodevelopment alterations. 
Finally, in caudate-putamen and olfactory bulb an MD decrease was detected, in 
line with hippocampus and cortex results from Tg2576 [138].  
3.8 Conclusions and future prospects 
3.8.1 Markers selection 
A number of animal models have been developed but none accurately reproduces 
human AD pathology. Although with some limitations, mouse models have 
provided valuable insights into different aspects of AD such as the synergistic 
effect between tau-related pathology and APP dysfunction in sporadic AD. 
Transgenic mice are also fundamental to test new drugs allowing translatable 
therapeutic considerations for patients. Considering that many aspects of AD 
pathophysiology are not clarified, it is difficult to develop a valid animal model and 
this might explain the unexpected results and failure of the numerous clinical trials 
carried out so far. In spite of these limitations and of the differences in brain size, 
disease complexity and progression, it is possible to identify homologous imaging 
biomarkers in humans and mice, key elements to predict reliable results in drug 
testing. To date, among the human imaging markers sensitive to disease 
progression, atrophy detected with MRI are the most validated surrogate outcomes 
for clinical trials [126]. Indeed, hippocampal atrophy detected by MRI has recently 
been accepted by the European Medicined Agency (EMA) for use in clinical trials in 
pre-dementia stage of AD (EMA/CHMP/SAWP/809208/2011). Unfortunately, it 
does not seem a reliable marker in mice where alterations of hippocampal 
formation morphometry are often related to neurodevelopmental rather than 
neurodegenerative events. More complex mouse models, such as inducible 
models, where the disease starts after the brain is fully mature, may overcome 
these neurodevelopmental limitations allowing the creation of appropriate models 
in which in vivo hippocampal atrophy detection can be used as a surrogate 
biomarker for AD progression. In the meanwhile, we can consider different local 
volume changes mimicking the human hippocampal rate of atrophy such as 
caudate-putamen and frontal cortex volumes decrease in TASTPM and 
TauPS2APP. As recently shown, MRI cortical thickness biomarker can predict the 
risk to develop the AD pathology in human [178]. Entorhinal cortex thickness 
seems a potential index of disease progression in all the transgenic mice 
considered in this study.  
The difficulty to define valid DTI outcomes begins from human field and relys on 
the lack of longitudinal studies, the impossibility to correlate DTI parameters 
changes to histological sections and the absence of a complete agreement 
between all the literature reports. In this scenario mouse models become essential 
given that histological evaluation, hence Aβ and DTI indices variation correlation, is 
possible. Alterations of corpus callosum and anterior commissure diffusion indices 
of TASTPM seems to reflect the human pathology and are supported by white 
matter injury as detected in the histological staining.  
In conclusion appropriate approaches with imaging analysis can satisfy the 
principle of the evaluation of homologous parameters in experimental models and 
in AD patients to help the translational research in the development of efficacious 
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therapies. Probably no single imaging marker will be sensitive enough to accurately 
evaluate pharmacological treatments but a collection of markers should be. The 
imaging “signatures” composed by  
- caudate-putamen and frontal cortex volume of TASTPM and/or TauPS2APP 
- entorhinal cortex thickness of TASTPM and/or PDAPP 
- anterior commissure and corpus callosum diffusion indices of TASTPM 
completed by functional (fMRI), electrophysiological and biological markers of 
disease progression could improve our predictive power in testing disease 
modifying drugs. 
As the amyloid hypothesis is one of main hypothesis being explored in the clinic, 
gamma secretase or BACE inhibitors or beta-amyloid antibodies will be used to 
validate the selected imaging markers. Further studies will then be conducted using 
other amyloid lowering agents, Tau kinase and neuroprotective drugs to test their 
predictive capacity in pharmacological interventions. 
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4 PART II: HUMAN IMAGING 
4.1 Introduction 
Longitudinal MRI studies in patients with MCI, who have a high risk of developing 
AD, will improve our capability to selectively quantify the pathological progressive 
changes and thus discover and define novel imaging indices of disease 
progression. Identifying biomarkers sensitive to disease progression is important to 
reduce sample size and follow-up length of the clinical trials hasting the clinical 
application of novel therapeutic agents. Targeting a specific patient population is 
difficult for a single centre and often required a multisite approach to increase the 
population and statistical power of the analysis where MRI scanner of different 
models and manufactures account for results variability. Other sources of variability 
could be (i) lack of MRI acquisition protocols harmonization, (ii) intra-site variability 
induced by intrinsic instability of hardware components and magnetic field, (iii) 
changes in subject positioning. The measure reproducibility is fundamental to 
detect real changes in patients during longitudinal studies and neither 
morphometric nor diffusion quantitative estimation reliability is trivial [179].  
In order to combine data obtain from 1.5T and 3T, the two widely available scanner 
for clinical and research purpose, efforts focused on reproducibility of 
morphometric and diffusion measures across field strengths have been done [180, 
181]. However, test-retest reliability of these measures across different 3T MRI 
scanners has been poorly investigated and thus its impact on statistical analysis is 
not clearly defined.  
Manual segmentation of specific brain structures on MRI made by trained raters, 
with its high inter-rater reliability, is considered as the gold standard by many 
neuroimaging studies [182, 183]. However, due to its time-costs, manual 
segmentations are not practically applicable for longitudinal studies involving many 
subjects and different brain structures. Several automated and semi-automated 
algorithms have been proposed [184-191]. Advances in automated software tools 
permit to detect regional brain atrophy in a single subject [187, 192] allowing their 
application as a diagnostic marker for AD [193]. Recently, a longitudinal image 
processing framework has been developed [194] showing a significant increase in 
precision and discrimination power when compared with tools originally designed 
for cross-sectional analysis. Despite the wide usage of automated techniques, the 
within and across site test-retest reliability of morphometry and diffusion measures 
has been poorly investigated and thus its impact on statistical analysis is not clearly 
defined.  
Previously across session reliability studies of T1-weighted 3D structural MRI data 
at 3T performed on the same scanner has been addressed mainly on Siemens TIM 
trio scanners [194-196] and only one study exists which investigated it on GE 
Excite scanner [197] (Table 8a). Regarding the longitudinal (LG) stream, current 
documented knowledge available from the literature suggests better reliability of 
the LG analysis from structural 3T MRI data but using special sequences at a 
single 3T site [198] and within-session variability [194]. 
To our knowledge, multi-site 3T DTI MRI studies evaluating across-session 
reproducibility are limited to few sites [199, 200], focused on young subjects and 
mostly used manual ROI selection [201, 202] (Table 8b) or dedicated to 
acquisitions with several averaged DTI scans [203].  
 54 
 
 
 
 
 
Table 8: Summary of studies that evaluated within-scanner across session 
test-retest reproducibility of 3T MRI morphometry (a) and diffusion (b) results 
on healthy subjects. Abbreviations: CS, cross-sectional analysis; LG, longitudinal 
analysis, WB= whole brain, cc_body= body of the corpus callosum, cc_genu= genu 
of the corpus callosum, cc_spl= splenium of the corpus callosum, crtsp= 
corticospinal tract, ILF= inferior lateral fasciculus, SLF= superior lateral fasciculus. 
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4.2 Part II: Human imaging study goals 
The choice of human data acquisition and data analysis strategies can affect 
reproducibility errors and is therefore crucial in longitudinal studies aimed at 
evaluating MRI-derived biomarkers for disease progression and/or treatment 
efficacy. Here we present work aimed at implementing standardized procedures to 
acquire and analyze multi-site structural and diffusion 3T MRI data for automated 
brain analysis.  
In particular, this study involves 8 different 3T MRI sites (with Siemens, Philips and 
GE scanners) and each site scanned a group of elderly subjects scanned twice 
(test/retest design) at least a week apart to investigate reliability of the MRI-derived 
measures. The main goals of this are the following: 
- Use the multi-site structural MRI to evaluate and compare the across-session 
test-retest reproducibility of brain segmentations derived from FreeSurfer using the 
cross-sectional (CS) and longitudinal (LG) analysis streams [2]. The morphometric 
data evaluated includes subcortical, ventricular and intracranial volumes as well as 
cortical thickness. The main hypothesis to test is: does the LG segmentation 
improve the reliability of the brain segmentations (relative to the CS analysis) within 
all MRI sites to produce also an improvement of the data when pooled across MRI 
sites?  
- Use the diffusion tensor imaging MRI data (single acquisition during each test and 
retest session) to evaluate the across-session test-retest reproducibility of 
fractional anisotropy (FA), mean diffusivity (MD, 10-3 mm2/s), parallel (λII, 10-3 
mm2/s) and axial (λ┴, 10-3 mm2/s) diffusivities. The main hypothesis to test is: with 
the used acquisition and analysis protocol, are the reproducibility measures 
consistent with those reported in other similar studies?   
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4.3 Materials and methods 
4.3.1 Subjects 
Eight clinical sites participated in this study across Italy (Brescia, Verona, Genoa), 
Spain (Barcelona), France (Marseille, Lille, Toulouse) and Germany (Leipzig, 
Essen). The Brescia site was responsible for the coordination and analysis of the 
whole study and did not acquire MRI data. Each MRI site recruited 5 local 
volunteers within an age range of 50-80 years. The subject’s age range 
corresponds to the same one of the clinical population that will be studied with the 
protocols tested in this reproducibility study. Each subject underwent two MRI 
sessions completed at least a week apart at the site, to minimize biological 
changes that could affect the reliability of the measures. Table 9 summarizes 
information about age, gender and test-retest interval times of the subjects 
recruited at each site. All participants were healthy volunteers with no history of 
major psychiatric, neurological or cognitive impairment, and provided written 
informed consent in accordance with the "classification" of the study as regards to 
the national regulations and laws in the different participating countries. In France, 
the study required an authorization from the national drug regulatory agency 
(Agence Nationale de Sécurité du Médicament et des produits de santé) and an 
approval from the Comité de Protection des Personnes Sud-Méditerranée 1 
(Marseille), for the three French sites (Marseille, Lille, and Toulouse). In Germany, 
Spain and Italy the study required authorization from one Ethics Committee 
relevant to each institution: Essen (Ethik-Kommission des Universitätsklinikums 
Essen), Leipzig (Ethik-Kommission der Universität Leipzig), Barcelona (Comité de 
Etica e Investigación Clínica Hospital Clínic de Barcelona), Brescia (Comitato Etico 
Istituzioni Ospedaliere Cattoliche, CEIOC) and Genoa (Comitato Etico IRCCS-
Azienda Ospedaliera Universitaria San Martino-IST). 
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Table 9: Summary of demographic, MRI system and acquisition differences 
across MRI sites. 
4.3.2 MRI acquisitions 
The eight 3T MRI sites that participated in this study used different MRI system 
vendors and models (Siemens, GE, and Philips). Table 2 summarizes the main 
MRI system differences across sites. Each MRI scanning session consisted of 
several acquisitions, including: anatomical T2*, anatomical FLAIR, resting state 
fMRI, B0 map, DTI and two anatomical T1 scans, with a total acquisition time of 
approximately 35 minutes. The two anatomical T1 scans were used for brain 
morphometry analysis (3D MPRAGE: sagittal acquisition, square FOV = 256 mm, 
1x1x1 mm3, TR/TI = 2300/900 ms, flip angle= 90, no fat suppression, full k-space, 
no averages). These parameters were largely based on the MPRAGE 
recommendations from ADNI 2 (http://adni.loni.ucla.edu/research/protocols/mri-
protocols/) except for two factors: nominal spatial resolution (we used isotropic 1 
mm3 instead of 1x1x1.2 mm3) and image acceleration (when allowed by the RF coil 
we used an acceleration factor of two, instead of no acceleration). The main 
motivations for using acceleration were that most modern 3T scanners allow for it, 
and the reduction of scanning time is expected to reduce the sensitivity to head 
motion artifacts, even at an expense of some loss in signal.  
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The single DTI scan was used for brain diffusion analysis (b-value= 700 s/mm2, 5 
b0 volumes, 30 gradient directions, 2x2x2mm3, acceleration factor 2 (GRAPPA, 
SENSE and ASSET in Siemens, Philips and GE systems, respectively), axial slice 
acquisition. The parallel acquisition methods were different across sites, the 
choices were made based on the optimal or possible options available at the 
different platforms (see Table 9). All images from multi-channel coils were 
reconstructed by the scanner as the sum of the squares across channels. When 
allowed by the MRI system, images were reconstructed and saved without 
additional filtering options.  
4.3.3 Data preparation 
Imaging data were initially anonymized at each site by replacing the subject name 
with a unique identifier using the free DicomBrowser tool 
(http://hg.xnat.org/dicombrowser). Anonymized dicom data were then compressed 
and uploaded on to a data sharing system accessible to all member sites, from 
where they were subsequently downloaded for analysis at central site (Brescia).  
Downloaded anonymized dicom data were converted to nifti format using the free 
dcm2nii software 
(http://www.mccauslandcenter.sc.edu/mricro/mricron/dcm2nii.html, output format 
FSL – 4D NIFTI nii) from which the original dicom converted to nifty files were 
utilized. All data were visually inspected for quality assurance prior to analyses to 
check that there were no mayor visible artifacts, including motion, wrap around, RF 
interference and signal intensity or contrast inhomogeneities. For diffusion images 
motion for the subjects during the acquisition was also performed. Each subject 
had a total of four anatomical scans (two from the test session and two from the 
retest session) and two diffusion scans (one from the test and one from the retest 
session). No within-session averaging was done. 
4.3.4 Data post-processing 
4.3.4.1 Volumetric Measurement 
Each MPRAGE anatomical volume was analyzed in FreeSurfer [204, 205] to 
automatically generate subject-specific cortical [192, 206] and subcortical  [187] 
ROIs. For each subject we used two FreeSurfer analysis streams: the cross-
sectional (CS) stream, which treats each segmentation independently and the 
longitudinal-stream (LG), which creates a within-subject template from the CS 
results as prior knowledge to drive the segmentation of multiple time points, 
allowing for improved within-session test-retest reproducibility of morphometric 
results relative to the CS analysis [194].  
Our study is focused on a subset of the segmented regions which are of interest in 
neurodegenerative diseases. The volumetric ROIs included the hippocampal 
formation, amygdala, caudate nucleus (caudate), putamen, globus pallidus 
(pallidum), thalamus, lateral ventricles and total intracranial volume. The cortical 
ROIs included the parahippocampus gyrus, fusiform gyrus, superior temporal 
gyrus, precuneus, superiorparietal gyrus, supramarginal gyrus, lateral occipital 
gyrus, lingual gyrus and superior frontal gyrus [207]. For each of these structures 
(except the intracranial volume) the right and left hemisphere volumes are 
estimated separately on each anatomical scan. A total of 318 brain volumes were 
processed (8 MRI sites, 5 subjects per site, 4 volumes per subject and 2 
processing streams). The segmentation results were visually inspected prior to the 
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volume and thickness analysis to confirm that no mayor errors were present. No 
manual edits were done. All analyses were done using FreeSurfer version 5.1, 
running on a Linux workstation (Ubuntu 10.04) equipped with Intel CPU 8 x 3.07 
GHz processors and 7.9 GB of RAM. 
4.3.4.2 Diffusion data analysis: estimation of structural connectivity 
measures  
Data analysis of each DTI volume included Eddy current and motion correction 
followed co-registration to an ICBM atlas and estimation of FA, MD (10-3 mm2/s), λII  
(10-3 mm2/s) and λ┴ (10-3 mm2/s) from a full-brain voxel-based track-based spatial 
statistics (TBSS) analysis [4]. Each site’s FA maps were projected into a common 
site-specific white matter (WM) skeleton using randomized 5000 permutations. 
Atlas-based WM regions of interest (ROIs) were defined for each subject and 
session by linear co-registration of the JHU-ICBM-1mm atlas to each subject’s 
space. The ROI analysis was focused on the corpus callosum (body, genu and 
splenium), corticospinal tract (left/right), inferior and superior lateral fasciculi 
(left/right). Each site’s reproducibility mean was the average across subjects. 
 
 
 
Fig 23. Examples of b0 image of an healthy volunteer overlaided with the 
atlas-based masks used for the automatic diffusion quantification. 
Abbreviations: cc_body= body of the corpus callosum, cc_genu= genu of the 
corpus callosum, cc_spl= splenium of the corpus callosum, crtsp= corticospinal 
tract, ILF= inferior lateral fasciculus, SLF= superior lateral fasciculus. 
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4.3.5 Evaluation of reliability 
To evaluate the reliability of the brain segmentation and diffusion results we 
analyzed their variability, or reproducibility error, across the test-retest sessions for 
each site. There are several sources of variability for a fixed scanner, which include 
variability from hydration status (expected to be small if scans are repeated within a 
short time interval), variability due to slightly different acquisitions in the two 
sessions (head position change in the scanner, motion artifacts, scanner instability, 
etc.), and finally variability due to the imaging processing methods themselves. In 
addition, in a multi-center study there is also the added variability from the different 
MRI systems (vendor, model, acquisition parameters). In this study the goals were 
to evaluate the across session reliability of FreeSurfer brain segmentations, within 
each site and across sites, both for the CS and LG processing streams and the 
across session reliability of diffusion parameters extracted using an atlas-based 
ROIs method.  
Since every subject had segmentation results derived separately from each of the 
two test and the two retest MPRAGE volumes, we used these four possible test-
retest comparisons across sessions to estimate a mean across-session variability 
error per subject. For diffusion reliability was simpler because we had one test and 
one retest. As variability error we used the dimensionless measure of absolute 
percent change of volume (or thickness or diffusion) of a structure with respect to 
its average. In other words, for each subject and for each structure the across-
session variability error was estimated as follows: 
 
 
where the indices i and j can take values 1 or 2 to refer to the first or second 
MPRAGE volume (or thickness or diffusion index) in each of the test (Vtest) and 
retest (Vretest) sessions. The group variability error for every MRI site and brain 
structure was then averaged across subjects, within each analysis stream (or 
diffusion parameter) separately. Such estimation of variability can be interpreted as 
the mean measurement error. The measure was chosen because it is intuitive and 
because the estimation of the means is more robust than the estimation of the 
variance from the signed differences, in particular for low number of subjects.  
Another way to study measure reproducibility is using the coefficient of variation 
(CV) or the intraclass correlation coefficient (ICC). The former describes the 
dispersion of the values while the latter expresses which part of variance can be 
explained by biological variation between subjects rather than by measurement 
error within subjects. CV and ICC for diffusion measures were estimated as follow:  
 
 
(6) 
(7) 
(9) 
(8) 
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where σ is the standard deviation and µ the mean between test and retest, MS(B) 
is the between subjects mean square, MS(W) is the within subject mean square 
and m is the number of the observations per subject. For test-retest data on 
healthy elderly acquired at the same scanner using the same DTI sequence, the 
biological variation should be small and the and CV and ICC should be high.  
The distributions of volume (or thickness) differences plotted against volume (or 
thickness) means across sessions were examined with a Bland-Altman analysis 
[208]. These plots show the spread of data, the mean difference and the limits of 
agreement, and were used to confirm that the distributions were approximately 
symmetric around zero, that there were no outliers. 
An additional evaluation of variability was done by computing the spatial 
reproducibility of the segmented subcortical and ventricular volumes or the of the 
white matter ROIs. Spatial reproducibility was examined computing the Dice 
coefficients for the volume overlap [209] on the co-registered test-retest volumes 
segmented with both the Freesurfer streams. Similar analysis was done for 
diffusion ROIs where Dice coefficient was performed on the co-registered test-
retest ROIs. In particular, given two different labels (test and retest sessions) of a 
structure from the same subject, denoted by Vtest and Vretest the Dice coefficient 
is given by [209]: 
 
 
For identical spatial labels, D(Vretest, Vtest) achieves its maximum value of one, 
with decreasing values indicating less perfect overlap. For each subject the Dice 
coefficients were calculated as an average across the right and left hemispheres. 
The group results for each site where generated by averaging the Dice coefficients 
across subjects for each structure.  
4.3.6 Statistical analysis 
The following statistical analyses tests were done, using matlab and SPSS 
(v.13.0): 
• To test for MRI site effects on subject’s age distributions, a one-way 
analysis of variance (ANOVA) was used, with MRI site as factor. 
• To test for MRI site effects of mean volume, mean thickness, mean FA, 
mean MD, mean λII, mean λ┴, mean reproducibility error (of volumes, 
thickness and DTI parameters) and mean spatial overlap, a one-way 
Kruskall-Wallis test (non-parametric version of ANOVA) was used with MRI 
site as factor. 
• To test for differences between the mean reproducibility error of the two 
Freesurfer streams (LG vs. CS) for each structure and site, the two-tailed 
Wilcoxon test was used (non-parametric version of the paired Student’s t-
test). 
 
 
 
(8) 
(9) 
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4.4 Results 
In this study, we estimate the test-retest reliability of morphometry and diffusion 
measures derived from 3T MRI data on healthy elderly volunteers scanned in two 
separate sessions at least one week apart at different MRI sites (eigth 3T MRI 
scanners from different vendors: GE, Siemens, Philips). This short period between 
the test and retest sessions was chosen to minimize biological changes that could 
affect the reliability of the measures and to mimic the variability expected from 
separate sessions, which are common in longitudinal studies. Moreover, for 
morphometry analysis, was evaluated how the reproducibility error is affected by 
Freesurfer processing stream (CS, LG). The 40 subjects enrolled (5 for each 
center, see Table 9 for summary demographic information) had similar age 
distribution except for site 2 (older group, mean age 74.6 ± 2.7 years, significantly 
different from sites 5, 6, 7, 8, ANOVA, p<0.05) and site 8 (younger group, mean 
age 52.4 ± 1.5 years, significantly different from sites 1, 2 , 3, 4, ANOVA, p<0.05). 
There were no age distribution differences between the other MRI sites. The 
overall mean time interval between the test and retest sessions was 17 days. 
4.4.1 Morphometry Results 
One goal was to compute and evaluate the segmentations of a total of 320 brain 
volumes: 8 MRI sites, 5 subjects per site, 4 acquisitions per subject (two test, two 
retest), 2 Freesurfer segmentation analysis protocols. In practice we had 3 missing 
volumes: two subjects of site 5 had missing MPRAGE volume repetitions during 
the test session, and one MPRAGE from site 1 failed the segmentation for 
unknown reasons. Visual inspection of Freesurfer segmented images showed a 
high similarity of results quality across sites (Fig 24). 
 
 
 
Figure 24: Sample MPRAGE images and Freesurfer segmentation results across 
different 3T MRI sites for qualitative comparison. Abbreviations: Hp= hippocampus, 
Amy= amygdala, Cau= caudate, Put= putamen, Pal= pallidum, Thal= thalamus, 
Lat= lateral ventricle, Ctx= cerebral cortex. See Table 2 for MRI sites 
characteristics. 
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4.4.1.1 Estimation of brain morphometric volumes across MRI sites 
Table 10 summarizes the group mean volumetric results (subcortical, ventricle and 
intracranial), averaged across hemispheres and across the test-retest sessions, for 
each MRI site as derived from the Freesurfer LG segmentation stream. A Kruskall-
Wallis test for MRI site effect on the hemispheric volumes showed that there were 
significant site effects (p<0.01) for only 2 of the 15 structures evaluated: the left 
putamen and right pallidum. This variability of morphometric results across sites is 
consistent with the fact that the groups of subjects were different at the various 
sites, and might simply reflect anatomical variability. 
 
 
 
Table 10: Volume estimates across sites. Within-site group means and standard 
deviation (across subjects, scanner sessions and hemispheres) of subcortical, 
ventricle and intracranial volumes derived from the Freesurfer longitudinal 
segmentation stream.  Abbreviations: Hp= hippocampus, Amy= amygdala, Cau= 
caudate, Put= putamen, Pal= pallidum , Thal= thalamus, Lat= lateral ventricle, 
ICV= intracranial volume. See Table 2 for MRI sites characterization. 
 
4.4.1.2 Estimation of volume reproducibility: effects of MRI sites and 
segmentation analyses 
Figure 25 shows an example of a Bland-Altman plot for a single site on two sample 
structures: the hippocampus (left) and the amygdale (right). The plot shows, for site 
2, the distribution of across-session volume differences relative to the volume 
means for the two analysis streams, CS (top) and LG (bottom). For each brain 
hemisphere (left: red crosses, right: blue circles) the mean volume difference (solid 
horizontal line) and the limits of agreement (±2 standard deviations, interrupted 
horizontal lines) are shown. The 20 data points in each plot correspond to the 5 
subjects and their respective 4 test-retest possible comparisons. As it can be seen, 
there are no outliers (all data points within 3 standard deviations) and the volume 
differences are symmetrically distributed around zero. Similar results were found 
for other sites and structures. In this example it is also possible to see how the 
spread of the data is reduced in the LG relative to the CS analysis. 
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Figure 25: Sample distribution of cross-sectional (CS) and longitudinal (LS) 
volume reproducibility results (Site 2) in hippocampus (Hp) and amygdala (Amy):  
Bland-Altman plots showing volume difference versus volume mean (two single 
MPRAGE acquisitions per session, subjects, n=5). For each brain hemisphere (left: 
red crosses, right: blue circles) the mean volume difference (solid horizontal line) 
and the limits of agreement (±2 standard deviations, interrupted horizontal lines) 
are shown. For reference, zero volume difference is shown as a black dotted line. 
 
Table 11 summarizes the across-session test-retest reproducibility errors of the 
various segmented volumes for each site, for both analysis streams (CS and LG). 
In each site the mean reproducibility error is computed as a mean across subjects, 
across the four test-retest segmentations and across the two brain hemispheres 
where relevant (intracranial volume is the only exception). No significant MRI site 
effects were found on the reproducibility error, regardless of structure and analysis 
stream used for the brain segmentations (Kruskall-Wallis test, p<0.01). Averaging 
the errors across sites allows to summarize the effects of analysis on the various 
structures (Table 3, last column). For all structures the LG stream showed a 
significantly lower reproducibility error relative to the CS stream (Wilcoxon test, 
p<0.01), except for the lateral ventricule volumes, which gave no significant 
differences between analyses streams. When considering the separate 
hemispheric volumes within each site and test across all structures, we also found 
that in all sites the LG analysis gave significantly lower reproducibility errors 
relative to the CS analysis (Wilcoxon test, p<0.05). 
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Table 11: Brain volumetric reproducibility errors for the various 3T MRI sites 
derived from the cross-sectional (CS) and longitudinal (LG) Freesurfer 
segmentations. Within each site the mean reproducibility errors is computed 
across subjects, across the four test-retest acquisitions and across brain 
hemispheres. There are no significant MRI site effects, regardless of analysis 
(Kruskall-Wallis test, p<0.01). The last column shows the reproducibility errors for 
each site and analysis when averaged across sites. Except for the lateral 
ventricles, for all other structures the reproducibility errors of LG are significantly 
lower than those from CS analysis (Wilcoxon test, p<0.01), Abbreviations for the 
segmented volumes: Hp= hippocampus, Amy= amygdala, Cau= caudate, Put= 
putamen, Pal= pallidum , Thal= thalamus, Lat= lateral ventricle volume. See Table 
2 for MRI sites characterization. 
 
Figure 26 illustrates in a plot an example of the findings reported in Table 3, 
showing the distribution of volumetric reproducibility errors (%) across the eight 
MRI sites for just two structures, the hippocampus (left) and the amygdale (right). 
Each point represents an MRI site, with the longitudinal error on the vertical axis 
and the cross sectional error along the horizontal axis, with corresponding within-
site standard deviations. The diagonal unity line corresponding to perfect 
agreement between the two measures is plotted as a thin reference line. The fact 
that the overall reproducibility error is smaller with the longitudinal line can be 
easily seen by having all dots under the unity line. The vertical and horizontal 
dotted lines mark the maximum range of the spread in absolute errors. It can be 
seen that the spread of errors for the longitudinal stream (range along vertical axis) 
is smaller than the spread of errors given by the cross-sectional stream (range 
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along horizontal axis). Overall this means that for the across-session test-retest 
errors in volumetric estimates the longitudinal stream gives lower reproducibility 
errors and also lower variability across MRI sites. 
 
 
Figure 26: Across-session test-retest reproducibility errors of hippocampus 
and amygdale volume estimates, effects of MRI site and processing stream. 
Reproducibility errors from the longitudinal and cross-sectional analysis for each 
one of the eight 3T MRI sites, with their respective within-site standard deviations. 
Data derived from Table 11. 
 
4.4.1.3 Estimation of spatial reproducibility of volumetric 
segmentations: effects of MRI sites and segmentation analyses 
The across-session test-retest spatial overlaps for both analysis streams are 
reported in Table 12, which shows for each site, structure and analysis the mean 
Dice coefficient of spatial overlap averaged across subjects, across the 4 test-
retest scans and across hemispheres. There were no significant MRI site effects of 
the Dice coefficients, regardless of analysis stream and structure (Kruskall-Wallis 
test, p<0.01). When averaged across MRI sites, the LG analysis showed 
significantly higher spatial reproducibility relative to the CS analysis, for all brain 
structures evaluated (Wilcoxon test, p<0.01). When grouping hemispheric 
structures within each site separately we also found that the spatial reproducibility 
of the LG analysis was significantly higher than that obtained with the CS analysis 
(Wilcoxon test, p<0.02).  
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Table 12: Spatial reproducibility of volumetric segmentations. Within-site 
group mean volume overlap (DICE coefficient) and standard deviation 
(across subjects, scanner sessions and hemispheres) derived from the 
Freesurfer cross-sectional (CS) and longitudinal (LG) segmentation streams. 
There are no significant MRI site effects, regardless of structure and analysis 
(Kruskall-Wallis test, p<0.01). The last column shows the spatial reproducibility for 
each site and analysis when averaged across sites. For all structures the spatial 
reproducibility was significantly higher with the LG analysis relative to the CS 
analysis (Wilcoxon test, p<0.01), Abbreviations: Hp= hippocampus, Amy= 
amygdala, Cau= caudate, Put= putamen, Pal= pallidum , Thal= thalamus, Lat= 
lateral ventricle volume. See Table 2 for MRI sites characterization. 
 
4.4.1.4 Estimation of cortical thicknesses across MRI sites 
Table 13 summarizes the group mean cortical thickness results, averaged across 
hemispheres and across the test-retest sessions, for each MRI site as derived from 
the Freesurfer LG segmentation stream. The A Kruskall-Wallis test for MRI site 
effect on the hemispheric volumes showed that there were significant site effects 
(p<0.01) for only 3 of the 18 cortical structures evaluated: the right/left fusiform and 
the right superior frontal gyrus. This variability of morphometric results across sites 
is consistent with different degrees of anatomical variability from the different 
groups scanned at the different sites. 
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Table 13: Cortical thickness estimates across sites. Within-site group means 
and standard deviation (across subjects, scanner sessions and 
hemispheres) of cortical thickness derived from the Freesurfer longitudinal 
segmentation stream. Abbreviations: Fus= Fusiform gyrus, LatOc= 
Lateraloccipital gyrus, Ling= Lingual gyrus, Parahp= Parahippocampal gyrus, 
Prec= Precuneus, SupFr= Superiorfrontal gyrus, SupPar= Superiorparietal gyrus, 
SupTem= Superiortemporal gyrus, Supra= Supramarginal gyrus. See Table 2 for 
MRI sites characterization. 
 
4.4.1.5 Estimation of thickness reproducibility: effects of MRI sites and 
segmentation analysis 
Figure 27 shows an example of a Bland-Altman plot for a single site on two sample 
cortical structures: the supramarginal gyrus (left) and the precuneus (right), The 
plot shows, for site 2, the distribution of across-session thickness differences 
relative to the thickness means for the two analysis streams, CS (top) and LG 
(bottom). For each brain hemisphere (left: red crosses, right: blue circles) the mean 
thickness difference (solid horizontal line) and the limits of agreement (±2 standard 
deviations, interrupted horizontal lines) are shown. The 20 data points in each plot 
correspond to the 5 subjects and their respective 4 test-retest possible 
comparisons. As it can be seen, there are no outliers (all data points within 3 
standard deviations), the thickness differences are symmetrically distributed 
around zero. In this example it is also possible to see how the spread of thickness 
data is very similar in the LG and CS analyses. 
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Figure 27: Sample distribution of cross-sectional (CS) and longitudinal (LG) 
thickness reproducibility results (Site 2) in supramarginal gyrus (Supra) and 
precuneus (Prec): Bland-Altman plots showing thickness difference versus 
thickness mean (two single MPRAGE acquisitions per session, subjects, n=5). For 
each brain hemisphere (left: red crosses, right: blue circles) the mean volume 
difference (solid horizontal line) and the limits of agreement (±2 standard 
deviations, interrupted horizontal lines) are shown. For reference, zero volume 
difference is shown as a black dotted line. 
 
Table 14 summarizes the mean across-session test-retest reproducibility errors in 
the cortical thickness estimates. For each site the mean error is averaged across 
subjects, across the four test-retest scans and across brain hemispheres. No 
significant MRI site effects were found on the reproducibility error, regardless of 
structure and analysis stream used for the brain segmentations (Kruskall-Wallis 
test, p<0.01). When averaged across MRI sites, the LG and CS analysis gave no 
significant differences in the thickness reproducibility (Wilcoxon test, p<0.01). 
When hemispheric structures were grouped and analyzed for each site separately 
we found that in four MRI sites the thickness reproducibility error was lower with 
the LG stream relative to the CS stream (Wilcoxon test, p<0.02), and not 
significantly different in the other four sites.  
 
 70 
 
 
Table 14: Effects of MRI site and processing stream on thickness 
reproducibility. Within-site group mean reproducibility error and standard 
deviation (across subjects, scanner sessions and hemispheres) derived from the 
Freesurfer cross-sectional (CS) and longitudinal (LG) segmentation streams. There 
are no significant MRI site effects, regardless of structure and analysis (Kruskall-
Wallis test, p<0.01). The last column shows the spatial reproducibility for each site 
and analysis when averaged across sites. No significant differences were found 
between the thickness reproducibility errors from LG and CS analyses when 
grouped across sites (Wilcoxon test, p<0.01). Abbreviations: Fus= Fusiform gyrus, 
LatOc= Lateraloccipital gyrus, Ling= Lingual gyrus, Parahp= Parahippocampal 
gyrus, Prec= Precuneus, SupFr= Superiorfrontal gyrus, SupPar= Superiorparietal 
gyrus, SupTem= Superiortemporal gyrus, Supra= Supramarginal gyrus. See Table 
2 for MRI sites characterization. 
 
Figure 28 is similar to Figure 26, and it used to illustrate in a plot an example of the 
findings reported in Table 15. The figure shows the distribution of cortical thickness 
reproducibility errors (%) across the eight MRI sites for just two structures, the 
supramarginal gyrus (left) and the precuneous (right). Each point represents an 
MRI site, with the longitudinal error on the vertical axis and the cross sectional error 
along the horizontal axis, with corresponding within-site standard deviations. As it 
can be seen, the distribution of errors falls above and below the unity line, and the 
spread of errors of both analysis streams are comparable. In other words, the 
cross-sectional and longitudinal analysis streams do not give big differences in the 
across-session test-retest reproducibility errors of cortical thickness estimates.  
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Figure 28: Across-session test-retest reproducibility errors of supramarginal 
gyrus and precuneus thickness estimates, effects of MRI site and processing 
stream. Reproducibility errors from the longitudinal and cross-sectional analysis for 
each one of the eight 3T MRI sites, with their respective within-site standard 
deviations. Data derived from Table 14. 
4.4.2 Diffusion results 
The main goals of this diffusion study were two: i) implement standardized 
procedures to acquire and analyze longitudinal multi-site diffusion 3T MRI data, 
and ii) evaluate the within and across-site across-session reproducibility of DTI-
derived metrics typically used to characterize structural connectivity. The analysis 
was aimed at a total of 80 brains: 8 MRI sites, 5 subjects per site, 2 acquisitions 
per subjects (one test, one retest). The DTI-derived metrics included: fractional 
anisotropy (FA), mean diffusivity (MD, 10-3 mm2/s), parallel (λII, 10-3 mm2/s) and  
axial (λ┴, 10-3 mm2/s) diffusivities. These metrics were evaluated and averaged for 
each subject and session in a number of gray and white matter ROIs taken from an 
atlas and considering relevance for MCI and AD studies. Four different analyses 
were used to characterize the across-session test-retest reliability on a single-
subject basis: i) absolute differences relative to the mean in %, ii) intra class 
correlation (ICC), iii) coefficient of variation (CV), and iv) spatial reproducibility of 
the ROIs (Dice coefficients). 
Preliminary quality assurance was done by inspecting each dataset for full brain 
coverage. We found that 6 DTI volumes had to be discarded from the analysis 
because of acquisition errors (partial brain coverage). Motion parameters estimated 
during the Eddy correction step were also inspected, indicating that, except for 
three sites, all maximum translations/rotations were below 1 mm/degrees (Table 
15). Visual inspection of FA images showed a high qualitative similarity of results 
quality across sites (Fig 29). 
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Figure 29: Sample single-subject FA maps across different 3T MRI sites for 
qualitative comparison. See Table 2 for MRI sites characteristics. 
 
 
Table 15. Head motion parameters across MRI sites. Maximum head rotations 
and translations across all subjects at each site. 
4.4.2.1 Estimation of brain diffusion parameters across MRI sites 
Table 16 summarizes the group mean diffusion results averaged across test-retest 
session for each MRI sites. Values were consistent across sites and metrics and 
Kruskall-Wallis test for MRI site effect on the hemispheric diffusion indices did not 
show any significant effect. 
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Table 16: Diffusion parameters estimates across sites. Within-site group 
means and standard deviation (across subjects and scanner sessions) of FA, MD 
(10-3 mm2/s) (a), λII (10-3 mm2/s) and λ┴ (10-3 mm2/s) (b). There are no significant 
MRI site effects (Kruskall-Wallis test, p<0.01). Abbreviations: cc_body= body of the 
corpus callosum, cc_genu= genu of the corpus callosum, cc_spl= splenium of the 
corpus callosum, crtsp= corticospinal tract, ILF_L= left  inferior lateral fasciculus, 
ILF_R= right  inferior lateral fasciculus, SLF_L= left superior lateral fasciculus, 
SLF_R= right superior lateral fasciculus. See Table 2 for MRI sites 
characterization. 
4.4.2.1 Estimation of brain diffusion parameters reproducibility across 
MRI sites 
The across-session test-retest reliability errors of the DTI indices are reported in 
Table 17, which shows for each structure and site, the mean absolute 
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reproducibility (%) across subjects. We found that the absolute reproducibility 
errors of FA, MD, λII and λ┴ in white matter ROIs were highly consistent across 
structures, metrics and 3T MRI sites, and was mostly within the range 2-3%. A 
Kruskall-Wallis test for MRI site effect on the hemispheric regions showed a 
significant site effects (p<0.01) for 3 of the 9 regions considered: body (MD, p= 
0.033; λ┴, p=0.018), splenium (λII, p= 0.022) and left superior lateral fasciculi (MD, 
p= 0.012; λ┴, p= 0.003). Fig 30 summarized the reproducibility error of FA, MD, λII 
and λ┴ for each site across the 9 white matter ROIs. No site effect was evident 
(Kruskall-Wallis test, p< 0.01). 
a 
 
 
 
b 
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Table 17: Effects of MRI site on diffusion reproducibility.  Within-site group 
mean reproducibility error and standard deviation (across subjects and scanner 
sessions). The abbreviations are the same of Table 16. See Table 2 for MRI sites 
characterization. 
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Figure 30: Summary of MRI site effects on diffusion reproducibility. Within-
site group mean reproducibility error (across-session test-retest) and standard 
deviation (across subjects, structures and sessions). There are no significant MRI 
site effects (Kruskall-Wallis test, p<0.01). See Table 2 for MRI sites 
characterization. 
 
4.4.2.2 Estimation of CV and ICC: effects of MRI sites 
In addition to the absolute reproducibility error, the ICC and CV were used to 
characterize the reliability of the DTI estimates. Table 18 shown the mean ICC and 
and the mean CV across sites and structures. Values were consistent across sites 
and metrics. There were no significant MRI site effects (Kruskall-Wallis test, 
p<0.01) for ICC while for CV a site effect was evident for MD (Kruskall-Wallis test, 
p= 0.006), λII (p= 0.023) and λ┴ (p= 0.016). 
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Table 18:  ICC and CV of WM ROIs. Within-site group mean ICC and CV and 
standard deviation of FA, MD, λII, λ┴ (across subjects, structures and scanner 
sessions). See Table 2 for MRI sites characterization. 
4.4.2.3 Estimation of spatial reproducibility of atlas-based ROIs: effects 
of MRI sites 
The across-session test-retest spatial overlaps are reported in Table 19, which 
shows for each site and ROI the mean Dice coefficient of spatial overlap averaged 
across subjects. A Kruskall-Wallis test for MRI site effect on the hemispheric 
volumes showed a significant site effects (p< 0.01) for 3 of the 9 regions 
considered: splenium, right corticospinal tract and left inferior lateral fasciculi.  
 
 
 
Table 19: Spatial reproducibility of WM ROI. Within-site group mean volume 
overlap (DICE coefficient) and standard deviation (across subjects and scanner 
sessions). The last row shows the spatial reproducibility for each site. The 
abbreviations are the same of Table 16. See Table 2 for MRI sites characterization. 
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4.5 Discussion 
4.5.1 Brain morphometry  
We show for the first time in a group of eight different 3T MRI scanners (Siemens, 
Philips, GE) that human subcortical volume and cortical thickness estimates 
derived from brain structural MRI data are remarkably reproducible when using the 
publicly available FreeSurfer automated segmentation tool. Specifically, using a 
group of healthy older (mean age 63.2 ± 8.1 years, n=40 where 5 sub/scanner) we 
examined how the subcortical, ventricular and intracranial volumes as well as 
cortical thickness test-retest reproducibility are affected by scan session, 
segmentation analyses and vendor. We demonstrate that longitudinal Freesurfer 
processing stream improve reliability relative to the cross-sectional segmentation 
stream, both within and across MRI sites. 
The segmentation errors reported in this work represent the best estimate we can 
give for the error of the method under the reported measurement conditions. The 
main factors that introduce errors in the final segmentation results are image 
quality factors (signal-to-noise ratio and contrast-to-noise ratio) and brain 
anatomical variability relative to the probabilistic atlas. These factors are 
intermingled. Realistic brain anatomical simulations with pre-defined characteristics 
for subcortical structures and their spatial arrangements could be attempted to 
separate the contribution of segmentation errors from image quality and 
segmentation atlas factors. These issues are important but are beyond the scope 
of this manuscript. The closest to a ground-truth that can be currently used to 
assess the accuracy of the FreeSurfer segmentation method is the comparison 
with manual segmentations by a neuroanatomist, as validated in Fischl et al. 2002 
[187]. 
The segmentation results of volumes (table 3) and thicknesses (table 6) are 
comparable with previously reported results (The Internet Brain Volume Database, 
http://www.cma.mgh.harvard.edu/ibvd/). For most structures, there's a fairly wide 
range of estimates of normal volume, and ours are within the typical range.  
Overall, there was consistent reliability of volumes for all regions considered across 
sites and vendors (table 4). For the hippocampus, thalamus, caudate, putamen, 
lateral ventricles and intracranial volumes, cross-sectional reproducibility error was 
less than 6%. As expected, higher variability has been revealed for smaller 
structures such as amygdale and pallidum (under 11.2%). Longitudinal pipeline, 
reducing the biological variabilities using the subject as his own control, 
significantly decreased reproducibility error in all regions. For bigger structure was 
less than 3% while for smaller regions was less than 6%. Our across session test-
retest reproducibility are comparable with previously within session reproducibility 
results performed using a Siemens TIM Trio scanner [194]. The spatial 
reproducibility results showed constant and high spatial consistency of the 
segmentation volumes already using the cross-sectional stream (mean Dice 
coefficient range across sites from 0.84 to 0.88) (Table 5), improved with the 
longitudinal pipeline (mean Dice coefficient range across sites from 0.90 to 0.95). 
Spatial overlap results are also in good agreement with a previous within session 
study [194]. 
The thickness reproducibility results were consistent for all regions across sites and 
vendors and were less than 5.51% (table 7). Unexpectedly, no significant 
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difference between the thickness reproducibility errors from the two analyses was 
found. This is in contrast to previous reported findings [194, 207] where a reduction 
of the thickness measurements variability was demonstrated. Several study 
differences may explain this discrepancy. Han et al used a lower field strength and 
considered the overall mean thickness measurement error while we analyzed 
single gyrus. Although Reuter et al used a 3T scanner, factors that could account 
on results differences are related to data collection (sample size and MPRAGE 
sequence) and to data analysis (they measured within session reproducibility). 
Indeed, their test-retest data derived from a set consisting of 115 controls scanned 
in the same site versus our 40, about which 5 subjects for each site. Moreover, 
within session acquisition is less affected by source of variance such as subject 
repositioning and magnetic field instability or drift.  
As recently shown, in vivo local structural 3D shapes characterization assessed 
differences between patients with AD and normal elderly individual [210, 211]. 
Hence, combining both volume and shape metrics might improve the power of 
detecting cross-sectional differences across populations or longitudinal changes. 
An important extension of the reproducibility study here presented would be to 
examine the reproducibility of shape metrics.  
4.5.2 Brain diffusion  
In this study we investigated how the test-retest quantitative estimation and 
reproducibility errors of FA, MD, λII and λ┴ derived from DTI data in a group of 
healthy older (mean age 63.2 ± 8.1 years, n=40 where 5 sub/scanner) are affected 
by 3T MRI scanners (Siemens, Philips, GE). As mentioned in the introduction, most 
multi-site DTI reproducibility studies have been performed at 1.5T [212-215], 
except for a few studies that used either limited number of MRI sites [200] or 
dedicated acquisitions with several averaged acquisitions [203]. Our reproducibility 
analysis was focused in different ROIs relevant to the study of neurodegenerative 
diseases like MCI and AD [216]: body, genu, splenium of the corpus callosum, 
corticospinal tract (left/right), inferior lateral fasciculus (left/right), superior lateral 
fasciculus (left/right). The goal was to evaluate and standardized an automatic 
procedure for the quantification of DTI indices which gave reproducibility results 
similarly to manually drawn ROIs studies. Fully automated procedures which avoid 
manual drawing of ROIs have the advantage of not requiring the presence of high 
inter- and intra-rater coefficient of variation to guarantee DTI parameters reliability. 
On the other hand, automated methods may be susceptible to partial volume 
effects at the edge of the anatomical structures. 
All DTI-derived metrics obtained from our acquisitions and analysis protocol (FA, 
MD, λ┴ and λII) were found consistent across MRI sites (Table 15a-b) and were 
comparable with previously reported DTI studies on healthy subjects of the same 
age [217, 218]. Overall, we found considerable consistency and good test-retest 
across session reproducibility of FA, MD, λII and λ┴  metrics across structures and 
3T scanners (table 16a-b and Fig 30). The absolute reproducibility errors of FA and 
MD in white matter ROIs were mostly within the range 2-3%, except for 
corticospinal tracts where the reproducibility error reached 7.99% for FA and 
14.95% for MD. Other 3T reproducibility studies on corpus callosum reported FA 
errors in the same range [200, 201]. Also CV in the corpus callosum was in good 
agreement with previous 3T [200, 201] and lower relative to 1.5T studies [212, 
213]. Besides corpus callosum, the CV of the other structures, excluding MD, λII 
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and λ┴ of corticospinal tracts, were below 10% which is desirable for biological 
variables related to imaging [219]. The ICC for most of the metrics was above 0.89 
with lower values for λ┴. ICC is more restrictive as reproducibility test and should 
be above 0.80 [219]. As in the multi-site 3T study (two identical GE scanners) of 
Vollmar et al, we detected lower reproducibility in smaller ROIs (i.e., corticospinal 
tracts) than in bigger ones (i.e., corpus callosum). Finally, comparisons among the 
four diffusion indices showed an higher reproducibility across different brain areas 
for FA and MD rather than axial or radial diffusivity (Table 16b and Fig 30). These 
parameters may be sensitive to scanner instability or to other systematic source of 
error such as body hydratation or  temperature of the subjects [219]. The spatial 
reproducibility was consistent across MRI sites. Again, the lower spatial overlap 
was detected in smaller tracts (i.e., corticospinal tracts), more sensitive to noise, 
and where fibers of different and crossing orientations were present (i.e., superior 
lateral fasciculi). This is due to an intrinsic limitation of the DTI technique where 
imaging of multiple fiber orientation in a single voxel is not possible. Diffusion 
Spectrum Imaging (DSI), a recent development of MRI, may overcome this 
problem.  
Extension of this work include understand possible sources of variability as well as 
further evaluation of reproducibility measures in gray matter, such as in the 
hippocampus. 
4.5.3 Limits of the study 
The major limit of this morphometric and diffusion study is the number of subject 
per site, an high number of subjects allow to minimize biases in the results. 
Besides, the volunteers are not the same for all sites including in our study 
biological variables due to obvious individual differences of the subjects. The 
optimal condition to make a test-retest reproducibility study should be organize a 
single group of healthy volunteers able to travel to the participating sites across the 
different countries.  
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4.6 Conclusions and future prospects 
Reliability of subcortical, ventricular and intracranial volumes as well as cortical 
thickness was high and unaffected by scanner of different vendors. Using the 
longitudinal stream of Freesurfer we improve the volume reproducibility for intra- 
and inter-site scanning achieving an averaged reproducibility errors for each site 
less than 4%.  
A multi-site 3T MRI protocol for brain DTI analysis was implemented in eight sites 
covering four countries. Our protocol considered single DTI acquisitions (no 
averages, approximately 5 min acquisitions each) and 8 different sites covering the 
most common clinical MRI vendors in Europe (Siemens, Philips, GE), both using 
old and very modern equipment. We found that the across-session test-retest 
reproducibility was comparable to that reported by other studies which used either 
low number of MRI sites or longer acquisitions.  
All these metrics will be assessed in the MCI longitudinal study already started in 
order to identify imaging markers to predict the conversion of MCI to AD and to 
map the disease progression from its earlier stages. 
Besides, being our morphometry and diffusion study an extension to the literature, 
suggests that the multi-site acquisition and analysis protocol used allows for 
reducing the number of subject that a single-site would need to detect a specific 
effect size by roughly the number of sites. 
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6 LIST OF TABLES AND FIGURES  
Figure 1. Hypothetical model of dynamic biomarkers in human AD (a) [13] 
and pathological AD progression in the most frequently used mice (b). 
Models of amyloidosis are created by deploying one, or a combination of, genes 
that have been found mutated in Familiar AD subjects (such as APP and PS1). 
These mice show structural, functional and biochemical alterations similarly to the 
human pre-clinical stage of AD pathology. Moreover, as for human, mouse deficits 
increase with age. All APP and/or PS1 Tg mouse models do not reproduce tangles. 
Tau pathology can be replicated in mice using modifications in the sequence of tau 
protein discovered in the familiar form of Frontotemporal Dementia with 
parkinsonism linked to chromosome 17 and Tau Tg mice are characterized by 
tangles in absence of Aβ. The triple transgenic mouse model, carrying mutation in 
APP, PS1 and Tau (3xTg) better reproduces the signature lesions of AD as it 
develops both Aβ and tangles. 
Figure 2. Structural markers in humans and mice. In humans, grey matter loss 
in regions such as hippocampus (hp), cortices (ctx) and whole brain (WB) is useful 
for defining the AD pathology and tracking its progression. The brain morphological 
alteration of Tg mice are linked with neurodevelopmental rather than 
neurodegenerative factors. Indeed, each Tg has a specific structural alteration 
signature and are described one by one. Volume decrease and increase are 
represented in red and blue colours respectively while no differences between Tg 
and controls are illustrated in green. Continuous line represents whole brain (WB), 
dotted line only posterior brain. The only mouse model exhibiting hippocampal 
volume decrease and deficits in cortical volume detected using MRI is the Inducible 
APPswe/Ind, where pathology develops when the brain has reached fully maturity. 
Figure 3. Functional and metabolic markers of preclinical AD in humans and 
homologous markers in Tg mice. Neuronal functionality is compromised many 
years before the appearance of clinical symptoms. Human studies found 
progressive functional impairment in the hippocampus (hp), posterior cingulate 
cortex (PCC), entorhinal cortex (ent) and temporo-parietal cortex (TP) of AD 
patients. The same areas were investigated in transgenic mice. 
Top: Functional markers of preclinical AD in humans. Middle: Mice strains where 
functional markers homologous to humans have been identified (e.g. metabolic 
deficits in the hippocampus of J20 and 3xTg mice). Bottom: Mice strains where the 
same markers have been evaluated giving opposite results in comparison with 
humans. Markers decrease and increase are represented with red and blue colours 
respectively. 
Fig 4. Some examples of sagittal (first row and bottom left) and coronal (second 
row middle and right) images of a young WT are shown with overlay of the masks 
used for the manual volume segmentation. Abbreviations: Cau-Put= caudate-
putamen, Hp= hippocampus, OB= olfactory bulb, ctx= cortex (except the frontal), 
Vent= lateral, third and fourth ventricles, WB= whole brain, ICV= intracranial 
volume. 
Fig 5. Examples of coronal color-coded images of a young WT are shown with 
overlay overlaided of the masks used for the manual diffusion quantification (black 
background) and 3D masks visualization (grey background). Abbreviations: cc= 
corpus callosum, ac= anterior commissure, cc= corpus callosum, cp= cerebral 
peduncle, ec= external capsule, fi= fimbria, int= internal capsule,  Cau-Put= 
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caudate-putamen, hp= hippocampus, OB= olfactory bulb, Frontal ctx= frontal 
cortex, Thal= thalamus, PIR= piriform cortex. 
Fig 6. Entorhinal cortex (ERC) thickness definition shown on a coronal image 
of a WT mouse. Abbreviation: rf = rhinal fissure. 
Fig 7. Comparison between TASTPM and WT normalized volumes across 
structures. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes derived from the manual segmentation. Axis y reported 
square root values. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's 
correction. Interaction p-values were also shown. The abbreviations were the same 
of Table 3. 
Fig 8. Representative T2-weighted images, FA maps and colour-coded FA 
from one coronal slice of young TASTPM and age-matched control. 
Fig 9. Automated FA and λ┴ maps comparisons between older TASTPM and 
age-matched controls. Coronal brain images overlaid with the skeleton (green) 
and with the TBSS results. Data showed significantly (p< .05) lower (red-yellow) FA 
and higher (light-blue) λ┴ values in external capsule, corpus callosum, fimbria and 
cerebral peduncle of TASTPM. 
Fig 10. DTI indices in the anterior commisure (ac) and corpus callosum (cc) 
of TASTPM and age-matched WT. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 
after Hochberg's correction. Interaction p-values are also shown. 
Fig 11. A representative comparison of amyloid load among older WT and 
different ages of TASTPM. Sagittal slices were immunostained with the 6E10 
antibody. TASTPM Tg mice display Aβ deposits which became visible at 9 months 
and increased with age. Even if the majority of the amyloid burdens was in the grey 
matter, deposits in white matter were clearly evident (magnification 4x; scale bar, 
250 µm). Abbreviations: Cau-Put= caudate-putamen, Hp= hippocampus, ctx= 
cortex, cc= corpus callosum, Thal= thalamus. 
Fig 12. A representative comparison of neuroinflammation among older WT 
and different ages of TASTPM. Sagittal slices were immunostained with Cd11b 
(a) and GFAP (b) antibodies. Microglial (arrow) and astrocytes (arrowhead) 
activation were observed when amyloid was present (magnification 4x; scale bar, 
250 µm). The abbreviations are the same of Fig 11. 
Fig 13. A representative comparison of myelinated axons among older WT 
and different ages of TASTPM. Sagittal slices were stained with Gold chloride. A 
progressive white matter disorganization starting at 13 months is observable in 
TASTPM Tg mice (magnification 4x; scale bar, 250 µm). The abbreviations are the 
same of Fig 11. 
Fig 14. Comparison between TauPS2APP and WT normalized volume 
estimations across structures. Within-site group means and standard deviation 
(across mice and hemispheres) volumes derived from the manual segmentation. 
Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. 
Interaction p-values were also shown. The abbreviations were the same of Table 3. 
Fig 15. A representative comparison of amyloid load among older mice. 
Sagittal slices were immunostained with the 6E10 antibody. Aβ deposits can be 
seen in corpus callosum, hippocampus, cortex, caudate-putamen and, to a lesser 
extent, in the thalamus (magnification 4x; scale bar, 250 µm). The abbreviations 
are the same of Fig 11. 
Fig 16. A representative comparison of neuroinflammation among older mice. 
Sagittal slices were immunostained with Cd11b (a) and GFAP (b) antibodies. Only 
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older TauPS2APP exhibited glial (arrow) and astrocytes (arrowhead) activation 
(magnification 4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
Fig 17. A representative comparison of myelinated axons among older mice. 
Sagittal slices were stained with Gold chloride. Any qualitative difference between 
TauPS2APP and WT can be appreciated (magnification 4x; scale bar, 250 µm). 
The abbreviations are the same of Fig 11. 
Fig 18. Comparison between PDAPP and WT normalized volume estimations 
across structures. Within-site group means and standard deviation (across mice 
and hemispheres) of volumes derived from the manual segmentation. Two-way 
ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. Interaction p-
values were also shown. The abbreviations were the same of Table 3. 
Fig 19. DTI indices in the corpus callosum (cc) and external capsule (ec) of 
PDAPP and age-matched WT. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after 
Hochberg's correction. Interaction p-values were also shown. 
Fig 20. A representative comparison of amyloid load among older WT and 
different ages of PDAPP. Sagittal slices were immunostained with the 6E10 
antibody. Few Aβ deposits can be seen only in the hippocampus of older PDAPP 
(magnification 4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
Fig 21. A representative comparison of neuroinflammation among older WT 
and different ages of PDAPP. Sagittal slices were immunostained with Cd11b (a) 
and GFAP (b) antibodies. No qualitative difference between TauPS2APP and WT 
can be appreciated (magnification 4x; scale bar, 250 µm). The abbreviations are 
the same of Fig 11. 
Fig 22. A representative comparison of myelinated axons among older WT 
and different ages of PDAPP. Sagittal slices were stained with Gold chloride. No 
qualitative difference between PDAPP and WT can be appreciated (magnification 
4x; scale bar, 250 µm). The abbreviations are the same of Fig 11. 
Fig 23. Examples of b0 image of an healthy volunteer overlaided with the 
atlas-based masks used for the automatic diffusion quantification. 
Abbreviations: cc_body= body of the corpus callosum, cc_genu= genu of the 
corpus callosum, cc_spl= splenium of the corpus callosum, crtsp= corticospinal 
tract, ILF= inferior lateral fasciculus, SLF= superior lateral fasciculus. 
Figure 24: Sample MPRAGE images and Freesurfer segmentation results 
across different 3T MRI sites for qualitative comparison. Abbreviations: Hp= 
hippocampus, Amy= amygdala, Cau= caudate, Put= putamen, Pal= pallidum, 
Thal= thalamus, Lat= lateral ventricle, Ctx= cerebral cortex. See Table 2 for MRI 
sites characteristics. 
Figure 25: Sample distribution of cross-sectional (CS) and longitudinal (LS) 
volume reproducibility results (Site 2) in hippocampus (Hp) and amygdala 
(Amy):  Bland-Altman plots showing volume difference versus volume mean (two 
single MPRAGE acquisitions per session, subjects, n=5). For each brain 
hemisphere (left: red crosses, right: blue circles) the mean volume difference (solid 
horizontal line) and the limits of agreement (±2 standard deviations, interrupted 
horizontal lines) are shown. For reference, zero volume difference is shown as a 
black dotted line. 
Figure 26: Across-session test-retest reproducibility errors of hippocampus 
and amygdale volume estimates, effects of MRI site and processing stream. 
Reproducibility errors from the longitudinal and cross-sectional analysis for each 
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one of the eight 3T MRI sites, with their respective within-site standard deviations. 
Data derived from Table 11. 
Figure 27: Sample distribution of cross-sectional (CS) and longitudinal (LG) 
thickness reproducibility results (Site 2) in supramarginal gyrus (Supra) and 
precuneus (Prec): Bland-Altman plots showing thickness difference versus 
thickness mean (two single MPRAGE acquisitions per session, subjects, n=5). For 
each brain hemisphere (left: red crosses, right: blue circles) the mean volume 
difference (solid horizontal line) and the limits of agreement (±2 standard 
deviations, interrupted horizontal lines) are shown. For reference, zero volume 
difference is shown as a black dotted line. 
Figure 28: Across-session test-retest reproducibility errors of supramarginal 
gyrus and precuneus thickness estimates, effects of MRI site and processing 
stream. Reproducibility errors from the longitudinal and cross-sectional analysis for 
each one of the eight 3T MRI sites, with their respective within-site standard 
deviations. Data derived from Table 14. 
Figure 29: Sample single-subject FA maps across different 3T MRI sites for 
qualitative comparison. See Table 2 for MRI sites characteristics. 
Figure 30: Summary of MRI site effects on diffusion reproducibility. Within-
site group mean reproducibility error (across-session test-retest) and standard 
deviation (across subjects, structures and sessions). There are no significant MRI 
site effects (Kruskall-Wallis test, p<0.01). See Table 2 for MRI sites 
characterization. 
 
 
Table 1. Most frequently used mice models of amyloidosis. PDGFβ (platelet-
derived growth factor β-chain) and PrP (prion protein) result in a transgene 
expression inside and outside of the central nervous system. Thy-1 (thymocyte 
differentiation antigen 1), HMG-CoA reductase (3 hydroxy-3-methylglutaryl-
coenzyme A reductase) and  NSE (neuron-specific enolase) are neuronal specific. 
Table 2. List of the transgenic mice and their respective controls included in this 
study, specified by animals per age, gender and study design. Abbreviations: CS= 
cross-sectional; LG= longitudinal. 
Table 3. Comparison between TASTPM and WT volume and thickness 
estimations. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes and thickness obtained from the manual segmentation. 
The ERC statistics refer to two-way ANOVA, **p<.01; ***p<.001 after Hochberg's 
correction. Abbreviations: Cau-Put= caudate-putamen, Hp= hippocampus, OB= 
olfactory bulb, Fron ctx= frontal cortex, ctx= rest of the cortex, Vent= lateral, third 
and fourth ventricles, WB= whole brain, ICV= intracranial volume, ERC= entorhinal 
cortex. 
Table 4. DTI indices of the white (a, b) and grey (c) regions of interest. MD, λII 
and λ┴ are expressed as 10-3mm2/s. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 
after Hochberg's correction. Interaction p-values are shown in the transgene x age 
column. Abbreviations: FA= fractional anisotropy, MD= mean diffusivity, λII= axial 
diffusivity, λ┴= radial diffusivity, cc= corpus callosum, ac= anterior commissure, 
cp= cerebral peduncle, cing= cingulum, int= internal capsule, ec= external capsule, 
fi= fimbria, Cau-Put= caudate-putamen, Hp= hippocampus, OB= olfactory bulb, 
Thal= thalamus, ns= non-significant. 
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Table 5. Comparison between TauPS2APP and WT volume estimations 
across structures. Within-site group means and standard deviation (across mice 
and hemispheres) of volumes and thickness derived from the manual 
segmentation. The ERC statistics refered to two-way ANOVA, **p<.01; ***p<.001 
after Hochberg's correction. The abbreviations were the same of Table 3. 
Table 6. DTI indices of the grey regions of interest. MD is expressed as 10-
3mm2/s. Two-way ANOVA, *p<.05; **p<.01; ***p<.001 after Hochberg's correction. 
Interaction p-values are shown in the transgene x age column. Abbreviations: Cau-
Put= caudate-putamen, Hp= hippocampus, Thal= thalamus, ns= non-significant. 
Table 7. Comparison between PDAPP and WT volume estimations across 
structures. Within-site group means and standard deviation (across mice and 
hemispheres) of volumes and thickness derived from the manual segmentation. 
The ERC statistics refer to two-way ANOVA, ***p<.001 after Hochberg's correction. 
The abbreviations were the same of Table 3. 
Table 8: Summary of studies that evaluated within-scanner across session 
test-retest reproducibility of 3T MRI morphometry (a) and diffusion (b) results 
on healthy subjects. Abbreviations: CS, cross-sectional analysis; LG, longitudinal 
analysis, WB= whole brain, cc_body= body of the corpus callosum, cc_genu= genu 
of the corpus callosum, cc_spl= splenium of the corpus callosum, crtsp= 
corticospinal tract, ILF= inferior lateral fasciculus, SLF= superior lateral fasciculus. 
Table 9: Summary of demographic, MRI system and acquisition differences 
across MRI sites. 
Table 10: Volume estimates across sites. Within-site group means and standard 
deviation (across subjects, scanner sessions and hemispheres) of subcortical, 
ventricle and intracranial volumes derived from the Freesurfer longitudinal 
segmentation stream.  Abbreviations: Hp= hippocampus, Amy= amygdala, Cau= 
caudate, Put= putamen, Pal= pallidum , Thal= thalamus, Lat= lateral ventricle, 
ICV= intracranial volume. See Table 2 for MRI sites characterization. 
Table 11: Brain volumetric reproducibility errors for the various 3T MRI sites 
derived from the cross-sectional (CS) and longitudinal (LG) Freesurfer 
segmentations. Within each site the mean reproducibility errors is computed 
across subjects, across the four test-retest acquisitions and across brain 
hemispheres. There are no significant MRI site effects, regardless of analysis 
(Kruskall-Wallis test, p<0.01). The last column shows the reproducibility errors for 
each site and analysis when averaged across sites. Except for the lateral 
ventricules, for all other structures the reproducibility errors of LG are signiciantly 
lower than those from CS analysis (Wilcoxon test, p<0.01), Abbreviations for the 
segmented volumes: Hp= hippocampus, Amy= amygdala, Cau= caudate, Put= 
putamen, Pal= pallidum , Thal= thalamus, Lat= lateral ventricle volume. See Table 
2 for MRI sites characterization. 
Table 12: Spatial reproducibility of volumetric segmentations. Within-site 
group mean volume overlap (DICE coefficient) and standard deviation (across 
subjects, scanner sessions and hemispheres) derived from the Freesurfer cross-
sectional (CS) and longitudinal (LG) segmentation streams. There are no 
significant MRI site effects, regardless of structure and analysis (Kruskall-Wallis 
test, p<0.01). The last column shows the spatial reproducibility for each site and 
analysis when averaged across sites. For all structures the spatial reproducibility 
was significantly higher with the LG analysis relative to the CS analysis (Wilcoxon 
test, p<0.01), Abbreviations: Hp= hippocampus, Amy= amygdala, Cau= caudate, 
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Put= putamen, Pal= pallidum , Thal= thalamus, Lat= lateral ventricle volume. See 
Table 2 for MRI sites characterization. 
Table 13: Cortical thickness estimates across sites. Within-site group means 
and standard deviation (across subjects, scanner sessions and hemispheres) of 
cortical thickness derived from the Freesurfer longitudinal segmentation stream. 
Abbreviations: Fus= Fusiform gyrus, LatOc= Lateraloccipital gyrus, Ling= Lingual 
gyrus, Parahp= Parahippocampal gyrus, Prec= Precuneus, SupFr= Superiorfrontal 
gyrus, SupPar= Superiorparietal gyrus, SupTem= Superiortemporal gyrus, Supra= 
Supramarginal gyrus. See Table 2 for MRI sites characterization. 
Table 14: Effects of MRI site and processing stream on thickness 
reproducibility. Within-site group mean reproducibility error and standard 
deviation (across subjects, scanner sessions and hemispheres) derived from the 
Freesurfer cross-sectional (CS) and longitudinal (LG) segmentation streams. There 
are no significant MRI site effects, regardless of structure and analysis (Kruskall-
Wallis test, p<0.01). The last column shows the spatial reproducibility for each site 
and analysis when averaged across sites. No significant differences were found 
between the thickness reproducibility errors from LG and CS analyses when 
grouped across sites (Wilcoxon test, p<0.01). Abbreviations: Fus= Fusiform gyrus, 
LatOc= Lateraloccipital gyrus, Ling= Lingual gyrus, Parahp= Parahippocampal 
gyrus, Prec= Precuneus, SupFr= Superiorfrontal gyrus, SupPar= Superiorparietal 
gyrus, SupTem= Superiortemporal gyrus, Supra= Supramarginal gyrus. See Table 
2 for MRI sites characterization. 
Table 15. Head motion parameters across MRI sites. Maximum head rotations 
and translations across all subjects at each site. 
Table 16: Diffusion parameters estimates across sites. Within-site group 
means and standard deviation (across subjects and scanner sessions) of FA, MD 
(10-3 mm2/s) (a), λII (10-3 mm2/s) and λ┴ (10-3 mm2/s) (b). There are no significant 
MRI site effects (Kruskall-Wallis test, p<0.01). Abbreviations: cc_body= body of the 
corpus callosum, cc_genu= genu of the corpus callosum, cc_spl= splenium of the 
corpus callosum, crtsp= corticospinal tract, ILF_L= left  inferior lateral fasciculus, 
ILF_R= right  inferior lateral fasciculus, SLF_L= left superior lateral fasciculus, 
SLF_R= right superior lateral fasciculus. See Table 2 for MRI sites 
characterization. 
Table 17: Effects of MRI site on diffusion reproducibility.  Within-site group 
mean reproducibility error and standard deviation (across subjects and scanner 
sessions). The abbreviations are the same of Table 16. See Table 2 for MRI sites 
characterization. 
Table 18:  ICC and CV of WM ROIs. Within-site group mean ICC and CV and 
standard deviation of FA, MD, λII, λ┴ (across subjects, structures and scanner 
sessions). See Table 2 for MRI sites characterization. 
Table 19: Spatial reproducibility of WM ROI. Within-site group mean volume 
overlap (DICE coefficient) and standard deviation (across subjects and scanner 
sessions). The last row shows the spatial reproducibility for each site. The 
abbreviations are the same of Table 16. See Table 2 for MRI sites characterization. 
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